var title_f37_25_38288="Aortic regurgitation CW Doppler";
var content_f37_25_38288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic regurgitation as demonstrated by continuous wave Doppler echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous wave Doppler in isolated aortic regurgitation. There is a moderate amount of aortic regurgitation based upon a diastolic deceleration rate that is moderately rapid. The peak velocity across the aortic valve is normal and there is no aortic stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38288=[""].join("\n");
var outline_f37_25_38288=null;
var title_f37_25_38289="Hidradenitis suppurativa";
var content_f37_25_38289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comedones and bridged scars in a flexure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ridley, CM, Neill, SM (Eds), The Vulva 2nd ed, Blackwell Science, Oxford, 1999, p.141.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38289=[""].join("\n");
var outline_f37_25_38289=null;
var title_f37_25_38290="Desquamation";
var content_f37_25_38290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Desquamation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Public Health Image Library (PHIL) file://phil.cdc.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38290=[""].join("\n");
var outline_f37_25_38290=null;
var title_f37_25_38291="Isoproterenol: Pediatric drug information";
var content_f37_25_38291=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoproterenol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"    see \"Isoproterenol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/46/8932?source=see_link\">",
"    see \"Isoproterenol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isuprel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        1",
"       </sub>",
"       &amp; Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bradyarrhythmias: Continuous I.V. infusion: 0.05-2 mcg/kg/minute; titrate to effect",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"      see \"Isoproterenol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bradyarrhythmias, AV nodal block, or refractory torsade de pointes: Continuous I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: 0.05-2 mcg/kg/minute; titrate to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 2-20 mcg/minute;  titrate to effect",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isuprel&reg;: 0.2 mg/mL (1 mL, 5 mL) [contains sodium metabisulfite; 1:5000]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: For continuous infusions, dilute in dextrose or NS to a maximum concentration of 20 mcg/mL; concentrations as high as 64 mcg/mL have been used safely and with efficacy in situations of extreme fluid restriction",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     20",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F184917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose 5%, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      2.5",
"     </sub>",
"     W,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5% and alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, atracurium, bivalirudin, caffeine citrate, cisatracurium, dexmedetomidine, famotidine, fenoldopam, heparin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, inamrinone, levofloxacin, milrinone, nitroprusside, pancuronium, potassium chloride, propofol, remifentanil, tacrolimus, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of asthma or COPD (reversible airway obstruction); ventricular arrhythmias due to A-V nodal block; hemodynamically compromised bradyarrhythmias or atropine-resistant bradyarrhythmias, temporary use in third degree A-V block until pacemaker insertion; low cardiac output or vasoconstrictive shock states",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isuprel&reg; may be confused with Disophrol&reg;, Isordil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F184916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, flushing, hyper-/hypotension, pallor, palpitation, paradoxical bradycardia (with tilt table testing), premature ventricular beats, Stokes-Adams attacks, tachyarrhythmia, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, nervousness, restlessness, Stokes-Adams seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia, serum glucose increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isoproterenol, other sympathomimetic amines, or any component; angina, pre-existing cardiac arrhythmias (ventricular); tachycardia or A-V block caused by cardiac glycoside intoxication; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in diabetics, renal or cardiovascular disease, hyperthyroidism, prostatic hypertrophy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolerance may occur with prolonged use; when discontinuing an isoproterenol continuous infusion used for bronchodilation, the infusion",
"     <b>",
"      must",
"     </b>",
"     be gradually tapered over a 24- to 48-hour period to prevent rebound bronchospasm; injection contains sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of Isoproterenol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Isoproterenol may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7732005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adequate studies have not been conducted in pregnant women; use during pregnancy when the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, respiratory rate, arterial blood gases, central venous pressure, ECG",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors resulting in relaxation of bronchial, GI, and uterine smooth muscle; increases heart rate and contractility; causes vasodilation of peripheral vasculature",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Immediately",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V. (single dose): Few minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By conjugation in many tissues including the liver and lungs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.5-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine principally as sulfate conjugates",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/46/8932?source=see_link\">",
"      see \"Isoproterenol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypotension is more common in hypovolemic patients",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1985, 76(3):409-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38291/abstract-text/2863296/pubmed\" id=\"2863296\" target=\"_blank\">",
"        2863296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13394 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38291=[""].join("\n");
var outline_f37_25_38291=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059534\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443754\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059528\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184850\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184835\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059538\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472667\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184917\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059537\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184919\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184916\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059542\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059527\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059526\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299548\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184844\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184846\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7732005\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059533\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059525\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059540\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059541\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059532\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059543\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13394|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=related_link\">",
"      Isoproterenol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/46/8932?source=related_link\">",
"      Isoproterenol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38292="Bronchoscopic cryosurgery: Indications, contraindications, and outcomes";
var content_f37_25_38292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38292/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38292/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38292/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38292/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38292/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38292/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/25/38292/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic cryosurgery (also known as cryotherapy) is a technique in which endobronchial tissue is destroyed by repeated freezing and thawing. It is useful for the ablation of endobronchial lesions, such as a malignant mass or benign tracheal stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The indications, contraindications, and outcomes of bronchoscopic cryosurgery are reviewed here, while the principles and technique are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Principles and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic cryosurgery is most often employed as a palliative therapy for airway obstruction due to a malignancy, usually in patients who cannot tolerate lung resection due to poor respiratory function or who are deemed inoperable due to the proximity of the tumor to the carina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/1-3,5,6\">",
"     1-3,5,6",
"    </a>",
"    ]. Suitable patients should have airway obstruction due to endobronchial disease; bronchoscopic cryosurgery has no role when the obstruction is due to external compression.",
"   </p>",
"   <p>",
"    Less common indications for bronchoscopic cryosurgery include airway obstruction due to benign endotracheal or endobronchial lesions, inoperable microinvasive carcinoma, and hemoptysis due to visible benign or malignant lesions. Cryoadhesion can be used to extract foreign bodies, mucous plugs, or blood clots. During cryoadhesion, the cryoprobe freezes the target material, causing the material to adhere to the probe. The material is extracted by removing the cryoprobe if a rigid bronchoscope is used, or by removing both the cryoprobe and bronchoscope as one unit if a flexible bronchoscope is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27894215\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic cryosurgery involves either flexible or rigid bronchoscopy, which typically requires general anesthesia or procedural sedation. Thus, contraindications to bronchoscopy, general anesthesia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    procedural sedation are also considered contraindications to bronchoscopic cryosurgery. These are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H4#H4\">",
"     \"Procedural sedation in adults\", section on 'Contraindications and precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few cryosurgery-specific contraindications. Cryosurgery should be avoided if tissue sloughing is likely to worsen impending respiratory failure; in this situation, a procedure that resects the tissue and immediately restores airway patency (eg, electrocautery, laser) would be more appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of bronchoscopic cryotherapy is generally determined by comparing the following factors before and after cryosurgery: endoscopic appearance, clinical status (ie, symptoms), radiologic appearance, respiratory function, and histologic appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway obstruction can be due to a malignant or benign lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5726063\">",
"    <span class=\"h3\">",
"     Malignant lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have found that cryotherapy is beneficial for airway obstruction due to malignant lesions, whether performed via rigid or flexible bronchoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryosurgery via rigid bronchoscopy &ndash; An uncontrolled trial of 33 consecutive patients who underwent 81 cryotherapy sessions found that airway obstruction was relieved in 77 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/9\">",
"       9",
"      </a>",
"      ]. Lung function and symptoms improved in approximately 60 percent of patients. Other studies (&gt;600 patients total) have reported subjective improvement in 65 to 78 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cryosurgery via flexible bronchoscopy &ndash; A study of 225 patients found that cryotherapy relieved the airway obstruction in more than 90 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/13\">",
"       13",
"      </a>",
"      ]. A smaller study with 22 patients similarly found that airway obstruction was relieved in approximately 90 percent of patients, after which lung function improved in 58 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited data suggest that chemotherapy may be more effective following cryotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It has been hypothesized that this is due to increased accumulation of the chemotherapeutic agent within the tumor following cryotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/16\">",
"     16",
"    </a>",
"    ]. This theory is supported by a study of 12 patients who had an inoperable endobronchial tumor obstructing a mainstem bronchus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/17\">",
"     17",
"    </a>",
"    ]. The patients were each given 15 mg of intravenous radiolabeled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , which was then detected in the tumor using a gamma-camera. This was repeated 15 days later, immediately following cryosurgery. The uptake of radiolabeled bleomycin was 30 percent higher following cryosurgery. The relationship between cryosurgery-induced accumulation of a chemotherapeutic agent and decreased tumor growth was confirmed in a series of animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryosurgery may also improve the effect of external beam radiation therapy. This was illustrated by a study of 38 patients with symptomatic, unresectable airway obstruction who underwent cryosurgery followed by radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/21\">",
"     21",
"    </a>",
"    ]. Among the 26 patients who had a good response to cryosurgery, local control of the tumor following radiation therapy occurred in 65 percent. This was better than in historical controls, among which local control of the tumor following radiation therapy occurred in only 35 percent. It has been hypothesized that the possible increased sensitivity to radiation therapy following cryosurgery may be a consequence of cryosurgery induced neovascularization (increased vascularization improves radiosensitivity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5726100\">",
"    <span class=\"h3\">",
"     Benign lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less evidence regarding airway obstruction due to benign lesions. Granulation tissue due to bronchial reimplantation following lobectomy or lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/23\">",
"     23",
"    </a>",
"    ] and endobronchial lipomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] have been successfully removed by bronchoscopic cryosurgery, according to case reports. However, some benign endobronchial lesions tend to be cryoresistant, such as those caused by fibrotic tissue. Bronchoscopic cryotherapy has had only moderate success in treating such lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard therapy for carcinoid tumors is surgery (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4153?source=see_link&amp;anchor=H1143201171#H1143201171\">",
"     \"Bronchial carcinoid tumors: Treatment and prognosis\", section on 'Surgical resection'",
"    </a>",
"    ). However, cryosurgery via rigid bronchoscopy has been evaluated as a potential alternative therapy. In an uncontrolled trial, 18 patients with typical endobronchial carcinoid underwent bronchoscopic cryosurgery and were followed for a mean of 55 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/26\">",
"     26",
"    </a>",
"    ]. Only one patient (6 percent) had a recurrence, which occurred seven years after the intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Foreign body removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cryoprobe can be used to remove foreign bodies by cryoadhesion (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications'",
"    </a>",
"    above), according to case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38292/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The easiest types of objects to remove are friable items or biologic matter, such as pills, peanuts, teeth, peas, seeds, and chicken bones. However, cryoadhesion cannot remove metal objects, such as some tooth caps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27894352\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoscopic cryosurgery (also known as cryotherapy) is a technique in which endobronchial tissue is destroyed by repeated freezing and thawing. It is useful for the ablation of endobronchial lesions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopic cryosurgery is most often employed as a palliative therapy for airway obstruction due to a malignancy. Other indications for bronchoscopic cryosurgery include airway obstruction due to a benign endobronchial lesion, inoperable microinvasive carcinoma, hemoptysis due to a visible lesion, and the extraction of foreign bodies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications to bronchoscopy, general anesthesia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      procedural sedation are contraindications to bronchoscopic cryosurgery. (See",
"      <a class=\"local\" href=\"#H27894215\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopic cryosurgery relieves malignant airway obstruction in approximately 90 percent of cases. Symptoms and lung function improve in the majority of these patients, as well. There is less evidence regarding the outcome of bronchoscopic cryosurgery performed for other indications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/2\">",
"      Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/3\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/4\">",
"      Nassiri AH, Dutau H, Breen D, et al. A multicenter retrospective study investigating the role of interventional bronchoscopic techniques in the management of endobronchial lipomas. Respiration 2008; 75:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/5\">",
"      Asimakopoulos G, Beeson J, Evans J, Maiwand MO. Cryosurgery for malignant endobronchial tumors: analysis of outcome. Chest 2005; 127:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/6\">",
"      Prakash UB. Advances in bronchoscopic procedures. Chest 1999; 116:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/7\">",
"      Hetzel M, Hetzel J, Schumann C, et al. Cryorecanalization: a new approach for the immediate management of acute airway obstruction. J Thorac Cardiovasc Surg 2004; 127:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/8\">",
"      Noppen M, Meysman M, Van Herreweghe R, et al. Bronchoscopic cryotherapy: preliminary experience. Acta Clin Belg 2001; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/9\">",
"      Walsh DA, Maiwand MO, Nath AR, et al. Bronchoscopic cryotherapy for advanced bronchial carcinoma. Thorax 1990; 45:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/10\">",
"      Maiwand MO, Homasson JP. Cryotherapy for tracheobronchial disorders. Clin Chest Med 1995; 16:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/11\">",
"      Rodgers BM, Moazam F, Talbert JL. Endotracheal cryotherapy in the treatment of refractory airway strictures. Ann Thorac Surg 1983; 35:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/12\">",
"      Mathur PN, Wolf KM, Busk MF, et al. Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Chest 1996; 110:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/13\">",
"      Schumann C, Hetzel M, Babiak AJ, et al. Endobronchial tumor debulking with a flexible cryoprobe for immediate treatment of malignant stenosis. J Thorac Cardiovasc Surg 2010; 139:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/14\">",
"      Benson JW. Combined chemotherapy and cryosurgery for oral cancer. Am J Surg 1975; 130:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/15\">",
"      Marasso A, Gallo E, Massaglia GM, et al. Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis. Indications, limits, personal experience. Chest 1993; 103:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/16\">",
"      Ikekawa S, Ishihara K, Tanaka S, Ikeda S. Basic studies of cryochemotherapy in a murine tumor system. Cryobiology 1985; 22:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/17\">",
"      Homasson JP, Pecking A, Roden S, et al. Tumor fixation of bleomycin labeled with 57 cobalt before and after cryotherapy of bronchial carcinoma. Cryobiology 1992; 29:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/18\">",
"      Forest V, Peoc'h M, Campos L, et al. Effects of cryotherapy or chemotherapy on apoptosis in a non-small-cell lung cancer xenografted into SCID mice. Cryobiology 2005; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/19\">",
"      Forest V, Peoc'h M, Ardiet C, et al. In vivo cryochemotherapy of a human lung cancer model. Cryobiology 2005; 51:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/20\">",
"      Forest V, Peoc'h M, Campos L, et al. Benefit of a combined treatment of cryotherapy and chemotherapy on tumour growth and late cryo-induced angiogenesis in a non-small-cell lung cancer model. Lung Cancer 2006; 54:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/21\">",
"      Vergnon JM, Schmitt T, Alamartine E, et al. Initial combined cryotherapy and irradiation for unresectable non-small cell lung cancer. Preliminary results. Chest 1992; 102:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/22\">",
"      Le Pivert PJ, Binder P, Ougier T. Measurement of intratissue bioelectrical low frequency impedance: a new method to predict per-operatively the destructive effect of cryosurgery. Cryobiology 1977; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/23\">",
"      Maiwand MO, Zehr KJ, Dyke CM, et al. The role of cryotherapy for airway complications after lung and heart-lung transplantation. Eur J Cardiothorac Surg 1997; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/24\">",
"      Franke KJ, Nilius G, R&uuml;hle KH. [Cryorecanalization of an endobronchial lipoma]. Pneumologie 2005; 59:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/25\">",
"      Taviot B, Coppere B, Pacheco Y, et al. [Tracheobronchial lipomatosis. Apropos of a case]. Rev Pneumol Clin 1987; 43:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/26\">",
"      Bertoletti L, Elleuch R, Kaczmarek D, et al. Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor. Chest 2006; 130:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/27\">",
"      Rafanan AL, Mehta AC. Adult airway foreign body removal. What's new? Clin Chest Med 2001; 22:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38292/abstract/28\">",
"      Weerdt, S, Noppen, M, Remels, L, et al. Successful removal of a massive endobronchial clot by means of cryotherapy. Journal of Bronchology 2005; 12:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4381 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38292=[""].join("\n");
var outline_f37_25_38292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27894352\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27894215\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5726063\">",
"      - Malignant lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5726100\">",
"      - Benign lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27894352\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4153?source=related_link\">",
"      Bronchial carcinoid tumors: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=related_link\">",
"      Bronchoscopic cryosurgery: Principles and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38293="Fibrinogen molecule schematic";
var content_f37_25_38293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Schematic model of fibrinogen and fibrin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fibrinogen consists of three pairs of polypeptide chains, A&alpha;, B&beta;, and &Gamma;. The amino-terminal regions of all six chains are joined in the central domain (E domain) by disulfide bonds and form a dimeric structure. The E domain contains the FPA and FPB sequences that are cleaved by thrombin (IIa). Carbohydrate groups (O) are located at one site on each of the &Gamma; and B&beta; chains. Thrombin-catalyzed conversion of fibrinogen to fibrin involves release of FPA and FPB. A nonsubstrate (\"secondary\") binding site for thrombin (IIa) is present in the E domain of a,&beta;-fibrin, and depends largely, if not entirely, on the presence of the b15-42 sequence (see text). The binding sites for factor IIa, tissue plasminogen activator (t-PA), factor XIII, and alpha 2 plasmin inhibitor (&alpha;2-PI), are indicated on the fibrinogen or fibrin molecule. The regions in the fibrinogen/fibrin molecule containing the platelet binding HHLGGAKQAGDV or RGD sequences are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mosesson, MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:179. Copyright &copy; 1992 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38293=[""].join("\n");
var outline_f37_25_38293=null;
var title_f37_25_38294="Massive blood transfusion";
var content_f37_25_38294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Massive blood transfusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38294/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38294/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38294/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38294/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38294/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38294/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/25/38294/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive transfusion, defined as the replacement by transfusion of more than 50 percent of a patient's blood volume in 12 to 24 hours, may be associated with a number of hemostatic and metabolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/1\">",
"     1",
"    </a>",
"    ]. Massive transfusion involves the selection of the appropriate amounts and types of blood components to be administered, and requires consideration of a number of issues including volume status, tissue oxygenation, management of bleeding and coagulation abnormalities, as well as changes in ionized calcium, potassium, and acid-base balance.",
"   </p>",
"   <p>",
"    An overview of massive transfusion is presented here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/2\">",
"     2",
"    </a>",
"    ]. Other issues related to the use of blood products are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RED CELL AND VOLUME REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of the deficit in blood volume with crystalloid volume expanders will generally maintain hemodynamic stability, while transfusion of red cells is used to improve and maintain tissue oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Each unit of packed cells contains approximately 200 mL of red cells and, in an adult, will raise the hematocrit by roughly 3 to 4 percentage points unless there is continued bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At rest, oxygen delivery is normally four times oxygen consumption, indicating the presence of an enormous reserve. Thus, if intravascular volume is maintained during bleeding and cardiovascular status is not impaired, oxygen delivery will theoretically be adequate until the hematocrit (packed cell volume) falls below 10 percent. This is because adequate cardiac output plus increased oxygen extraction can compensate for the decrease in arterial oxygen content.",
"   </p>",
"   <p>",
"    Oxygen release by transfused red cells is diminished compared with normal red cells. Storage reduces 2,3-bisphosphoglycerate (2,3-BPG) levels, leading to a leftward shift of the oxyhemoglobin dissociation curve. This abnormality, however, has not been shown to be clinically important as the transfused red cells regenerate 2,3-BPG to normal levels within six to 24 hours after transfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of red blood cells for transfusion\", section on '2,3 BPG concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These above considerations, however, represent the optimal clinical response to massive blood loss. An approach to the use of crystalloid and red cell transfusions in adult patients suffering from shock due to loss of circulating blood volume secondary to hemorrhage is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of red blood cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALTERATIONS IN THE COAGULATION SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient being massively transfused may present with preexisting coagulopathy because of activation of coagulation secondary to tissue trauma, prolonged hypoxia, hypothermia, massive head injury, or muscle damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such coagulopathy (eg, disseminated intravascular coagulation) may be suspected in these patients when there is microvascular oozing, prolongation of the PT and aPTT in excess of that expected by dilution, together with significant thrombocytopenia, low fibrinogen levels, and increased levels of D-dimer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8073?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Trauma and extensive surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Acute DIC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even if coagulopathy does not exist and coagulation parameters are normal before blood is replaced, coagulation abnormalities may be induced by the dilutional effects of blood replacement on coagulation proteins and the platelet count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This occurs because packed red cell transfusions are devoid of plasma and platelets, which are removed immediately after collection.",
"   </p>",
"   <p>",
"    Some patients who suffer massive trauma may present upon arrival at a trauma center with a coagulopathy of trauma which is not due to DIC or dilutional coagulopathy. This coagulopathy is caused by widespread tissue",
"    <span class=\"nowrap\">",
"     injury/trauma",
"    </span>",
"    and associated physiologic changes (ie, acidosis, hypothermia, consumption of coagulant proteins, and fibrinolysis) combined with extensive blood loss and dilutional effects of fluid replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effects of acidosis and hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both acidosis and hypothermia interfere with the normal functioning of the coagulation system. As examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acidosis (ie, excess protons) specifically interferes with the assembly of coagulation factor complexes involving calcium and negatively-charged phospholipids. As an example, the activity of the factor",
"      <span class=\"nowrap\">",
"       Xa/Va/prothrombinase",
"      </span>",
"      complex is reduced by 50, 70, and 90 percent at a pH of 7.2, 7.0, and 6.8, respectively.",
"     </li>",
"     <li>",
"      Hypothermia reduces the enzymatic activity of plasma coagulation proteins, but has a greater effect by preventing the activation of platelets via traction on the glycoprotein",
"      <span class=\"nowrap\">",
"       Ib/IX/V",
"      </span>",
"      complex by von Willebrand factor. In tests of shear-dependent platelet activation, this pathway stops functioning in 50 percent of individuals at 30&ordm; C, and is markedly diminished in most of the rest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Coagulation proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The replacement of blood loss with red cells and a crystalloid volume expander will result in gradual dilution of plasma clotting proteins, leading to prolongation of the prothrombin time (PT) and the activated partial thromboplastin time (aPTT). In an adult, there will be an approximate 10 percent decrease in the concentration of clotting proteins for each 500 mL of blood loss that is replaced. Additional bleeding based solely on dilution can occur when the level of coagulation proteins falls to 25 percent of normal. This usually requires 8 to 10 units of red cells in an adult.",
"   </p>",
"   <p>",
"    Thus, the PT, aPTT, and fibrinogen should be monitored in patients receiving massive blood transfusions of this magnitude. Two units of fresh frozen plasma (FFP) should be given if the values exceed 1.5 times control. Each unit (in an adult) will increase the clotting protein levels by 10 percent. Cryoprecipitate or, when available, virus-inactivated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/20/14659?source=see_link\">",
"     fibrinogen concentrate",
"    </a>",
"    , may be used when fibrinogen levels are critically low (ie, &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11520860#H11520860\">",
"     \"Disorders of fibrinogen\", section on 'Cryoprecipitate and FFP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11520867#H11520867\">",
"     \"Disorders of fibrinogen\", section on 'Fibrinogen concentrate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar dilutional effect on the platelet concentration can be seen with massive transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/14\">",
"     14",
"    </a>",
"    ]. In an adult, each 10 to 12 units of transfused red cells can produce a 50 percent fall in the platelet count; thus, significant thrombocytopenia can be seen after 10 to 20 units of blood, with platelet counts below",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    For replacement therapy in this setting, six units of whole blood derived platelets or one apheresis concentrate should be given to an adult; each unit should increase the platelet count by 5000 to",
"    <span class=\"nowrap\">",
"     10,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H106617583#H106617583\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Massive blood loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the massively transfused patient, assumptions about possible dilutional effects should be confirmed by measurement of the PT, aPTT, and platelet count after the administration of every five to seven units of red cells. Replacement therapy should not be based upon any formula (eg, one unit of fresh frozen plasma (FFP) for every four units of red cells), except perhaps in patients with severe trauma (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     FFP, platelets, and red cells in trauma patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;While replacement therapy with plasma, platelets, and red cells should not generally be based upon any set formula, results from a number of observational studies suggest that patients with severe trauma, massive blood replacement, and coagulopathy have improved survival when the ratio of transfused FFP (units) to transfused platelets (units) to red cells (units) approaches 1:1:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/9,15-20\">",
"     9,15-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 246 patients who presented to an Army combat support hospital in Iraq has produced some data to evaluate the merits of this regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/9\">",
"       9",
"      </a>",
"      ]. When patients who received massive transfusion were stratified by transfusion therapy regimen, patients who received a high ratio of FFP to red cells (median of 1:1.4) had a survival rate of 81 percent as compared with 66 percent for those with an intermediate ratio (median 1:2.5) and 35 percent for those who received a low ratio of FFP to red cells (median of 1:8).",
"     </li>",
"     <li>",
"      In a retrospective study of 467 massively transfused trauma patients, 30-day survival was increased in patients transfused at a high plasma:RBC ratio (ie, &ge;1:2) as well as in those transfused at a high platelet:RBC ratio (ie, &ge;1:2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/15\">",
"       15",
"      </a>",
"      ]. The combination of high plasma and high platelet to RBC ratios was associated with decreased truncal hemorrhage and increased 6-hour, 24-hour, and 30-day survivals, with no change in deaths due to multiple organ failure.",
"     </li>",
"     <li>",
"      In a retrospective study of 694 massively transfused trauma patients who did not receive fresh whole blood, those receiving a high ratio of apheresis platelets (equivalent to 6 units of pooled platelets) per stored red cell unit (ie, ratio &ge;1:8) had a higher 24-hour survival (95 percent) as compared with those receiving a medium (ie, ratio 1:16 to 1:8, 87 percent) or a low ratio (ie, &lt;1:16, 64 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/21\">",
"       21",
"      </a>",
"      ]. On multivariate analysis, higher plasma:red cell ratios and higher apheresis platelets:red cell ratios were both independently associated with improved survival at both 24 hours and 30 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such observations have led these and other authors to recommend that patients who have sustained severe traumatic injuries",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are likely to require massive transfusion receive a 1:1:1 ratio of FFP to platelets to RBCs at the",
"    <strong>",
"     outset",
"    </strong>",
"    of their resuscitation and transfusion therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/10,15,20,22-24\">",
"     10,15,20,22-24",
"    </a>",
"    ]. Since there are only a limited number of retrospective studies in patients requiring massive transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], the value of this approach is still controversial and remains to be proven. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Summary and recommendations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF CITRATE INFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large amounts of citrate are given with massive blood transfusion, since blood is anticoagulated with sodium citrate and citric acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/27\">",
"     27",
"    </a>",
"    ]. Metabolic alkalosis and a decline in the plasma free calcium concentration are the two potential complications of citrate infusion and accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pH of a unit of blood at the time of collection is 7.10 when measured at 37&ordm;C (7.6 at 1 to 6&ordm;C) due to citric acid present in the",
"    <span class=\"nowrap\">",
"     anticoagulant/preservative",
"    </span>",
"    in the collection bag. The pH then falls 0.1 pH",
"    <span class=\"nowrap\">",
"     unit/week",
"    </span>",
"    due to the production of lactic and pyruvic acids by the red cells. Acidosis does not develop in a massively bleeding patient even if \"acidic\" blood is infused as long as tissue perfusion is restored and maintained. In this setting, the metabolism of each mmol of citrate generates three meq of bicarbonate (for a total of 23 meq of bicarbonate in each unit of blood). As a result, metabolic alkalosis can occur if the renal ischemia or underlying renal disease prevents the excess bicarbonate from being excreted in the urine. This may be accompanied by hypokalemia as potassium moves into cells in exchange for hydrogen ions that move out of the cells to minimize the degree of extracellular alkalosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=see_link\">",
"     \"Potassium balance in acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Free hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Citrate binding of ionized calcium can lead to a clinically significant fall in the plasma free calcium concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23685?source=see_link\">",
"     \"Relation between total and ionized serum calcium concentration\"",
"    </a>",
"    .) This change can lead to paresthesias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac arrhythmias in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recommendations for citrate infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;By extrapolation from animal studies, it is possible to calculate the maximum transfusion rate which would permit a normal liver to metabolize excess citrate, thereby avoiding hypocalcemia. The maximum citrate infusion rate should be 0.02",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    per minute (since this represents the maximum rate of citrate metabolism) and the citrate concentration in whole blood is 15",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (0.015",
"    <span class=\"nowrap\">",
"     mmol/mL).",
"    </span>",
"    Thus:",
"   </p>",
"   <p>",
"    &nbsp;Maximum citrate infusion rate",
"    <span class=\"nowrap\">",
"     (mmol/kg",
"    </span>",
"    per min)",
"    <br/>",
"    &nbsp;= &nbsp; (mmol citrate per mL of blood &nbsp; x &nbsp; mL of blood infused per min) &nbsp; &divide; &nbsp; wt (kg)",
"   </p>",
"   <p>",
"    &nbsp;mL of blood infused per min &nbsp; = &nbsp; (0.02 &nbsp;&divide; &nbsp;0.015) &nbsp;x &nbsp;wt (kg) &nbsp; = &nbsp; 1.33 &nbsp;x &nbsp;wt (kg)",
"   </p>",
"   <p>",
"    For a 50 kg recipient with normal hepatic function and perfusion, the maximum rate of blood transfusion to avoid citrate toxicity is 66.5",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    which is equal to 8.9 units of whole blood per hour (450 mL per unit) and 33.3 units of red cells per hour (approximately 120 mL per unit). Thus, significant hypocalcemia should not develop in this setting except under extreme circumstances. However, the risk is substantially greater in a patient with either preexisting liver disease or ischemia-induced hepatic dysfunction. In such patients, the plasma ionized calcium concentration should be monitored and calcium replaced with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    if ionized hypocalcemia develops:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If 10 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      is used, 10 to 20 mL should be given intravenously (into another vein) for each 500 mL of blood infused.",
"     </li>",
"     <li>",
"      If 10 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"       calcium chloride",
"      </a>",
"      is used, only two to five mL per 500 mL of blood should be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     Calcium chloride",
"    </a>",
"    may be preferable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    in the presence of abnormal liver function, since citrate metabolism is decreased, resulting in slower release of ionized calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/2\">",
"     2",
"    </a>",
"    ]. Care must be taken to avoid administering too much calcium and inducing hypercalcemia, ideally by monitoring the ionized calcium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION OF HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid transfusion of multiple units of chilled blood may reduce the core temperature abruptly and can lead to cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, during massive transfusion, a commercial blood warmer should be used to warm blood toward body temperature during infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTION OF HYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and patients with renal impairment may develop hyperkalemia because of potassium leakage due to prolonged blood storage or irradiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of red blood cells for transfusion\", section on 'Potassium leakage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In these patients, the following steps can be used to minimize the risk of hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Select only red cells collected less than five days prior to transfusion.",
"     </li>",
"     <li>",
"      Any unit of red cells can be washed immediately before infusion to remove extracellular potassium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the patient who is being massively transfused requires careful and ongoing consideration of a number of complex physiological relationships. The primary concern is correction of ischemia which can be accomplished at the outset by aggressive volume expansion to maintain perfusion pressure as blood is being readied for infusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Parameters to monitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;As volume is replaced, attention must be paid to several parameters to allow successful resuscitation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best approach to blood transfusion in trauma is unknown. Transfusions are given based upon the patient's injuries and response to the initial transfusions, with attention being paid to any underlying cardiopulmonary disease.",
"     </li>",
"     <li>",
"      There is no clear threshold beyond which blood use is futile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The coagulation system should be frequently monitored with measurements of the PT, aPTT and platelet count, preferably after each five units of blood replaced. If the PT and aPTT exceed 1.5 times the control value, the patient should be transfused with at least two units of fresh frozen plasma. If the platelet count falls below",
"      <span class=\"nowrap\">",
"       50,000/microL,",
"      </span>",
"      six units of random donor platelets, or one unit of apheresis platelets, should be given.",
"     </li>",
"     <li>",
"      A blood warmer should be used whenever more than three units are transfused. Hypothermia should be either avoided or minimized.",
"     </li>",
"     <li>",
"      Acid-base balance and the plasma ionized calcium and potassium levels should be periodically monitored, particularly in patients with coexistent liver or renal disease or in those with massive hemorrhage and low cardiac output [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38294/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Severe trauma and coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the subset of patients who present with widespread tissue trauma (as in combat injuries) and who present with coagulopathy, a different approach to transfusion therapy has been advocated by the United States military. The treatment of such patients is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=see_link&amp;anchor=H62323474#H62323474\">",
"     \"Coagulopathy associated with trauma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/1\">",
"      Collins JA. Problems associated with the massive transfusion of stored blood. Surgery 1974; 75:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/2\">",
"      British Committee for Standards in Haematology, Stainsby D, MacLennan S, et al. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/3\">",
"      Stehling L. Fluid replacement in massive transfusion. Massive Transfusion AABB 1994; 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/4\">",
"      Lundsgaard-Hansen P. Treatment of acute blood loss. Vox Sang 1992; 63:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/5\">",
"      Hardy JF, De Moerloose P, Samama M, Groupe d'int&eacute;r&ecirc;t en H&eacute;mostase P&eacute;riop&eacute;ratoire. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2004; 51:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/6\">",
"      Miller RD, Robbins TO, Tong MJ, Barton SL. Coagulation defects associated with massive blood transfusions. Ann Surg 1971; 174:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/7\">",
"      Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979; 190:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/8\">",
"      Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. A study of 172 cases. Vox Sang 1982; 42:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/9\">",
"      Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/10\">",
"      Hess JR. Blood and coagulation support in trauma care. Hematology Am Soc Hematol Educ Program 2007; :187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/11\">",
"      Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/12\">",
"      Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/13\">",
"      Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/14\">",
"      Reed RL Jr, Ciavarella D, Heimbach DM, et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Ann Surg 1986; 203:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/15\">",
"      Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/16\">",
"      Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma 2009; 66:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/17\">",
"      Shaz BH, Dente CJ, Nicholas J, et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010; 50:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/18\">",
"      Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets--a review of the current literature. Transfusion 2010; 50:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/19\">",
"      Inaba K, Lustenberger T, Rhee P, et al. The impact of platelet transfusion in massively transfused trauma patients. J Am Coll Surg 2010; 211:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/20\">",
"      de Biasi AR, Stansbury LG, Dutton RP, et al. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME). Transfusion 2011; 51:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/21\">",
"      Perkins JG, Cap AP, Andrew CP, et al. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. J Trauma 2009; 66:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/22\">",
"      Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007; 62:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/23\">",
"      Johansson PI, Stensballe J, Rosenberg I, et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 2007; 47:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/24\">",
"      Yuan S, Ziman A, Anthony MA, et al. How do we provide blood products to trauma patients? Transfusion 2009; 49:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/25\">",
"      Schreiber MA, Perkins J, Kiraly L, et al. Early predictors of massive transfusion in combat casualties. J Am Coll Surg 2007; 205:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/26\">",
"      McLaughlin DF, Niles SE, Salinas J, et al. A predictive model for massive transfusion in combat casualty patients. J Trauma 2008; 64:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/27\">",
"      Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev 1988; 2:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/28\">",
"      Bruining HA, Boelhouwer RU, Ong GK. Unexpected hypopotassemia after multiple blood transfusions during an operation. Neth J Surg 1986; 38:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/29\">",
"      Howland WS, Schweizer O, Carlon GC, Goldiner PL. The cardiovascular effects of low levels of ionized calcium during massive transfusion. Surg Gynecol Obstet 1977; 145:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/30\">",
"      Boyan CP. Cold or warmed blood for massive transfusions. Ann Surg 1964; 160:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/31\">",
"      Como JJ, Dutton RP, Scalea TM, et al. Blood transfusion rates in the care of acute trauma. Transfusion 2004; 44:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38294/abstract/32\">",
"      Smith HM, Farrow SJ, Ackerman JD, et al. Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series. Anesth Analg 2008; 106:1062.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7931 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38294=[""].join("\n");
var outline_f37_25_38294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RED CELL AND VOLUME REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALTERATIONS IN THE COAGULATION SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effects of acidosis and hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Coagulation proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Platelet count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FFP, platelets, and red cells in trauma patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS OF CITRATE INFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Free hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recommendations for citrate infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION OF HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTION OF HYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Parameters to monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Severe trauma and coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38295="Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems";
var content_f37_25_38295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38295/contributors\">",
"     David L Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38295/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38295/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/25/38295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     UNEXPECTED RHYTHMS WITH NORMALLY FUNCTIONING DUAL-CHAMBER PACING SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of electrocardiographic findings and rhythms may be encountered in which the pacing system is functioning normally. These include cross talk, pacemaker-mediated or endless loop tachycardias, and repetitive non-reentrant ventriculo-atrial synchronous rhythms. These might be considered functional system malfunctions since the resulting arrhythmia may be deleterious to the patient, although the device is functioning normally and in accord with its programmed specifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Crosstalk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a DDD pacemaker, a paced or sensed event in one channel initiates one or more timing circuits in the opposite channel. As a result, the release of an atrial output pulse will initiate an AV delay, which will permit a ventricular output pulse at the end of this interval if an R wave is not sensed. A ventricular event that is sensed during the AV interval, considered to be an R wave, will cancel the AV interval, inhibit the ventricular output pulse, and cause the pacemaker to initiate an atrial escape interval.",
"   </p>",
"   <p>",
"    Current pacing systems, however, are incapable of recognizing morphologic characteristics of a complex. Any intrinsic complex, output decay, or artifact of electromagnetic interference of sufficient amplitude and frequency response that it is not filtered out by the sense amplifier is treated as a true signal. Although bipolar sensing configuration is believed to minimize far-field sensing, crosstalk can be seen with any sensing configuration. If any signal is interpreted as an R wave, and inhibits the ventricular output and resets the escape interval, the phenomenon is termed crosstalk-mediated ventricular output inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When AV nodal conduction is otherwise intact, crosstalk is asymptomatic. If there is first degree AV block, the effective paced rate may be slower than the programmed base rate, because the conducted R wave will occur after completion of the ventricular refractory period initiated by the oversensing of the atrial stimulus. The conducted R wave will be sensed, thereby resetting the atrial escape interval yet again. A clinical catastrophe may occur in the presence of complete AV block combined with cross talk (in the absence of safety-pacing), as the system will effectively pace the atrium, but the ventricular output may be repeatedly inhibited, leaving the patient asystolic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that predispose to cross talk associated with the atrial output include a high atrial output (either pulse amplitude, pulse duration, or both), the ventricular sensing channel programmed to a very sensitive setting, and a short ventricular blanking period. The ventricular blanking period is a very short interval of absolute refractoriness initiated in the ventricular sense amplifier upon completion of the atrial escape interval. It is designed to coincide with the atrial output pulse. The intent of the blanking period is to prevent sensing of the atrial stimulus and, hence, prevent cross talk. Ventricular blanking periods are often programmable. Lengthening the ventricular blanking period may avoid crosstalk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective method to prevent cross talk is to lengthen the ventricular blanking period. However, a ventricular premature beat that occurs within the ventricular blanking period may not be sensed if the intrinsic deflection of the VPB occurs during the blanking period. Events that are not sending during the blanking period is a form of functional undersensing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/4\">",
"     4",
"    </a>",
"    ]. It has the potential for inducing an adverse rhythm triggered by competition. Upon termination of the blanking period, the AC interval timer is allowed to complete, because nothing was sensed by the pacemaker, and a ventricular output pulse will be released. Depending upon the AC interval, this may place a ventricular stimulus on the apex of the T-wave and may induce pathologic ventricular tachyarrhythmias in the electrically unstable patient. Thus, the extended blanking period could have an adverse effect, even though the pacing system is functioning in accord with its design and programmed parameters and the occurrence of cross talk has been effectively prevented. Periods of forced inability to sense or inability to react to a sensed event (ie, refractory periods and blanking periods) should generally be kept as short as possible.",
"   </p>",
"   <p>",
"    Since the blanking periods for dealing with cross talk may be associated with potential problems, a special detection or sensing window on the ventricular channel that immediately follows the blanking period has been incorporated into dual-chamber pacing systems. If an event is sensed during this cross talk detection window, the logic incorporated in the pacemaker will treat this as if it were true cross talk. The event sensed during this special detection window causes the ventricular circuit to trigger a ventricular output pulse at the end of an abbreviated AV interval rather than inhibiting its output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This abbreviated AV interval will result in nonphysiologic AV sequential pacing, but will protect the patient from asystole in the presence of cross talk combined with complete heart block.",
"   </p>",
"   <p>",
"    If the sensed event were a true R wave, particularly a ventricular ectopic beat, the pacing stimulus occurring at a short AV interval would likely occur when the ventricular myocardium is physiologically refractory and would neither capture nor induce any dangerous arrhythmias. When a true R wave is present, rather than cross talk, the ventricular output that deforms the QRS-ST complex reflects normal sensing, but the pacemaker is automatically and transiently programmed to respond in the triggered mode during this very brief period. The overall phenomenon is generically called \"safety pacing\". In many pacing systems, this is a programmable parameter that can be enabled or disabled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inappropriate automatic mode switch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual chamber pacemakers capable of 'tracking' the atrial rhythm recognize very rapid atrial rates and can implement automatic mode switch when specific criteria are met. It is relatively common for the atrial channel of the pacemaker to \"see\" ventricular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/7\">",
"     7",
"    </a>",
"    ]. This is termed far field R wave (FFRW) sensing. In this setting, a normal rhythm may be double counted on the atrial channel, ie, the true P wave or atrial pacing pulse and the FFRW signal, inducing inappropriate mode switching.",
"   </p>",
"   <p>",
"    To manage this, contemporary pacemakers allow the absolute refractory period on the atrial channel, termed the post ventricular atrial blanking period (PVAB), to be programmed to a sufficiently long interval in order to preclude FFRW sensing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pacemaker-initiated tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemaker-initiated tachycardia can occur when competition, due to undersensing, functional or otherwise, triggers a native tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Once the tachycardia is initiated, the pacemaker becomes an innocent bystander, being inhibited by the native arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pacemaker-mediated tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pacemaker-mediated tachycardia (PMT) is a tachycardia that can only be sustained by the continued active participation of the pacemaker. There are two forms of PMT: endless loop tachycardia and tracking of a native atrial tachyarrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tracking of a native atrial tachyarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this type of arrhythmia, the pacemaker senses pathologic atrial activity, such as atrial fibrillation or atrial flutter, and in a patient with high-grade AV block, the pacemaker acts as an artificial bypass track, resulting in a paced tachycardia at or near the programmed maximum tracking rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The automatic mode switch algorithm effectively limits this form of PMT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Endless loop tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic form of pacemaker-mediated tachycardia is an endless loop tachycardia (ELT), which results from retrograde conduction from the ventricle to the atrium. The retrograde P wave is sensed by the pacemaker via the atrial lead, and an output to the ventricle is triggered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/13-21\">",
"     13-21",
"    </a>",
"    ]. The essential ingredients for an ELT are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The ability of the AV node to sustain retrograde conduction",
"     </li>",
"     <li>",
"      A retrograde P wave of sufficient amplitude to be sensed",
"     </li>",
"     <li>",
"      The occurrence of the retrograde P wave during the atrial alert period, which allows it to be sensed and to serve as a trigger to initiate the rhythm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most individuals with a normal heart are capable of demonstrating retrograde conduction in the appropriate circumstances. It does not occur during the normal synchronization between the atrium and ventricle, because atrial and AV nodal depolarization renders these tissues physiologically refractory.",
"   </p>",
"   <p>",
"    The most common cause of an ELT is a ventricular premature beat (VPB) occurring before the anticipated P wave; if the VPB is appropriately timed, occurring after the AV node and atrial myocardium have recovered, it may cause retrograde depolarization of these structures. Other events that may result in retrograde conduction include an atrial premature beat conducted with either a long PR interval (or PV interval) that permits an echo phenomenon, atrial undersensing or oversensing, and loss of atrial capture.",
"   </p>",
"   <p>",
"    There are two forms of ELT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic form, which results in PV pacing at the programmed maximum tracking rate. The sensed P wave is tracked, but the programmed AV interval is extended to delay release of the ventricular output pulse until the maximum tracking rate interval times out. This allows the atrial and AV nodal tissue to physiologically recover, enabling them to be depolarized by the next paced ventricular beat.",
"     </li>",
"     <li>",
"      A \"balanced\" endless loop tachycardia. If retrograde conduction is sufficiently slow and the combination of the retrograde VP and anterograde PV intervals exceeds the maximum tracking rate, an ELT can result that is slower than the maximum tracking rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variant of ELT has been observed in two patients with heart failure who were receiving cardiac resynchronization therapy (CRT) in which biventricular pacing was achieved with a standard DDDR pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In these cases, the atrial channel was connected to the left ventricular (LV) lead and the right ventricular (RV) lead was placed in the ventricular port of the connector block. This will not occur with contemporary devices designed with three channels (atrium, RV, and LV). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Management of an endless loop tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are a number of management options to prevent or terminate an ELT, the one absolute way to",
"    <strong>",
"     prevent",
"    </strong>",
"    an ELT is to program the post ventricular atrial refractory period (PVARP) sufficiently long to prevent the pacemaker from sensing and hence tracking the retrograde P wave. Extending the PVARP does not prevent retrograde conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A longer PVARP effectively lengthens the total atrial refractory period (TARP), thereby limiting the maximum atrial rate that can be sensed and tracked. If the reduction in the maximum paced atrial rate is not a clinical concern for the patient, increasing the length of the PVARP is often a definitive solution.",
"   </p>",
"   <p>",
"    However, many clinicians want the pacemaker to have a mean tracking rate that is higher than that allowed by programming a long PVARP. Since ELT is frequently initiated by VPBs, many manufacturers have incorporated automatic PVARP extensions following a VPB. For a pacemaker, a VPB is a sensed ventricular event (R wave) that is not preceded by any paced or sensed atrial activity. The various automatic PVARP extensions, while being effective in some cases, may simply postpone the ELT for one cycle and, more commonly, result in sustained pacemaker inhibition when the P wave is able to conduct with a first degree AV block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. The P wave is not seen by the pacemaker because it coincides with the PVARP. The resultant native ventricular depolarization, which is due to anterograde conduction is called a VPB by the pacing system, reinitiating the longer PVARP for that cycle and sustaining the pacemaker inhibition. However, since VPBs are not the only trigger for an ELT, this automatic post-VPB PVARP extension algorithm is usually only a partial solution.",
"   </p>",
"   <p>",
"    Another option for management includes making the atrial channel less sensitive. This may be successful if the retrograde P wave is known to be a lower amplitude than the anterograde or sinus P wave [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, this may result in loss of atrial sensing at higher rates, because the atrial electrogram amplitude can decrease at higher rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If increasing the PVARP to a sufficient degree to prevent sensing of the retrograde P wave is not an option for prevention of ELT, a variety of tachycardia termination algorithms have been developed. For example, with one common algorithm, after a given number of PV cycles at or above a PMT detection rate, the system automatically inhibits ventricular output for a single beat, extends the PVARP, or alters the PV interval. Algorithms have been effective in terminating a true ELT.",
"   </p>",
"   <p>",
"    If the tachycardia is a physiologic atrial rhythm that is being appropriately tracked, there will be an occasional pause in the rhythm in those systems that use an algorithm to either extend the PVARP or withhold a ventricular output pulse. The paced tachycardia will resume with the next cycle as the pacemaker tracks the native atrial rhythm. When the algorithm involves a subtle alteration in the PV interval, a physiologic tachycardia will be allowed to persist without creation of intermittent pauses in the rhythm.",
"   </p>",
"   <p>",
"    Shortening or lengthening the PV interval will have the opposite effect on the VP interval. In a true ELT, lengthening the PV interval will not alter the VP interval, because the P wave is triggered by the paced ventricular complex, rather than being independent. In this case, the PVARP lengthening is then initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Repetitive non-reentrant ventriculoatrial synchronous rhythms (AV desynchronization arrhythmia)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual chamber atrioventricular sequential pacing at relatively rapid rates, whether due to sensor drive or associated with a relatively high programmed base rate, sets the stage for an AV desynchronization arrhythmia, also called repetitive non reentrant ventriculoatrial synchronous rhythms, that may be hemodynamically deleterious and cause symptomatic palpitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/31\">",
"     31",
"    </a>",
"    ]. The occurrence of this arrhythmia requires intact retrograde VP conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. The pacing system is functioning normally in accord with its programmed parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the onset of RNRVAS, an event occurs that triggers one cycle of AV dissociation, resulting in retrograde conduction. The retrograde P wave coincides with the PVARP, precluding it from being sensed. This is intentional and functional undersensing. Hence, a PMT does not occur. However, the atrial depolarization renders the atrial myocardium physiologically refractory. As a result, there may be failure to capture with the next atrial stimulus, which occurs at the end of a relatively short atrial escape interval since the pacing rate is high and in close proximity to the intrinsic atrial depolarization. This is functional noncapture. The time from the atrial depolarization to the ensuing ventricular stimulus occurring at the end of the AV interval provides sufficient time for the atrial myocardium to recover, thereby allowing retrograde conduction to occur. This can result in a rhythm in which there is sustained retrograde conduction, followed each time by an ineffective atrial stimulus.",
"   </p>",
"   <p>",
"    The patient may experience palpitations from the retrograde conduction as the atrium contracts against a closed mitral and tricuspid valve, inducing cannon A waves. In addition, there may be hypotension and hemodynamic compromise due to the loss of optimal AV synchrony. Basically, this is a form of dual chamber pacemaker syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of an RNRVAS requires minimizing the duration of the refractory periods, allowing all native events to be sensed. If this results in an ELT, then a tachycardia termination algorithm should be used to terminate the PMT. If AVDA is consistently enabled by a true VPB, then a more specific post-VPB PVARP extension algorithm will prevent it. Most PVARP extensions lengthen the PVARP but do not alter the basic pacing interval that will simply sustain this problem because the atrial output pulse will still occur at a time when the atrial myocardium is physiologically refractory.",
"   </p>",
"   <p>",
"    A \"+PVARP on VPB\" algorithm lengthens the PVARP and adds an obligatory atrial alert period following the end of the extended PVARP. As a result, despite the programmed or sensor-driven AV pacing rate, the pacemaker is disabled in favor of an atrial escape interval defined by the \"+PVARP on VPB\" algorithm for this one cycle. When an atrial stimulus occurs at the end of this atrial escape interval, the atrial myocardium will have physiologically recovered, assuring atrial capture and preventing this arrhythmia. If a native P wave occurs during the atrial alert period, it is sensed and tracked. Either a paced or sensed atrial event will terminate this algorithm and return the pacing system to its previous functional state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Functional single chamber atrial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients who require a pacemaker have AV conduction that is prolonged, but intact. Such patients may pace their right ventricle a high percentage of the time. In recent years, it has been recognized that unnecessary ventricular pacing may increase the incidence of both atrial fibrillation and congestive heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/33-37\">",
"     33-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When AV nodal conduction is prolonged, but intact, and the QRS width is normal, programming the pacemaker to minimize ventricular pacing (ie, functional single chamber atrial pacing) is recommended. A number of techniques are used to achieve this end, and these may produce unexpected rhythms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Long programmed AV delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;One can achieve functional single chamber atrial pacing by simply programming a very long AV delay (ie, the amount of time after an atrial beat that the pacemaker will wait to sense an intrinsically conducted QRS before pacing the RV). This is a simple approach that can be limited by the pacemaker sensing the intrinsic RV activation late in the QRS. Thus, even if the PR interval is only slightly prolonged, the RV lead may not sense the QRS until more than 300 msec after the P wave. In such cases, it may be difficult or impossible to program a long enough AV delay to avoid ventricular pacing.",
"   </p>",
"   <p>",
"    Many patients with mild or moderate PR prolongation would do well most of the time with native conduction, and markedly reduced frequency of RV pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     AV/PV hysteresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With this feature, a basic AV delay is set, but periodically the system extends the AV delay by a programmed amount [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. If a native QRS is sensed during this extended interval, the pacemaker will continue to function with this longer AV delay, allowing native conduction and minimizing ventricular pacing. If AV block worsens, and ventricular pacing is again required, the pacemaker will return to the original, shorter AV delay for a period of time, then it will repeat the test with the longer AV",
"    <span class=\"nowrap\">",
"     delay.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     AAI/DDD pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAI/DDD",
"    pacing is the most commonly used technique to minimize ventricular pacing. There are subtle differences among the algorithms available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], but the basic design is similar. These devices will initially function as a single chamber, AAI pacemaker, but with continuous ventricular sensing. The system will not attempt to pace the ventricle unless sustained AV block develops (ie, it will allow long PR intervals, and even one or two non-conducted P-waves [dependent on algorithm]). If loss of AV conduction is sensed, the pacemaker will switch to DDD pacing for some period of time until the algorithm once again looks for intrinsic AV conduction. The rationale for this approach is that most patients will tolerate isolated pauses, and that it is more important to minimize ventricular pacing than it is to ensure that every P wave is followed by a sensed or paced QRS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link&amp;anchor=H13#H13\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Modes to minimize ventricular pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An example of a ventricular pacing avoidance algorithm in the setting of AV block is shown based on recordings from a Holter monitor (",
"    <a class=\"graphic graphic_waveform graphicRef68792 \" href=\"mobipreview.htm?1/32/1539\">",
"     waveform 1",
"    </a>",
"    ). Intermittent AV block was present that was not associated with ventricular pacing, but this is consistent with the normal behavior of this algorithm. On the atrial paced beat following a cycle of AV block, ventricular pacing occurs at a foreshortened AV delay of 80 ms despite the programmed AV delay. Sustained AV block will result in a reversion to the DDD mode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VENTRICULAR ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) and ventricular fibrillation (VF) are often preceded by abrupt changes in ventricular cycle lengths (ie, the interval between successive ventricular beats). These events are referred to as short-long-short (SLS) sequences. A common example of an SLS sequence involves ventricular premature beats. The \"short\" interval between a normal beat and a VPB is followed by a \"long\" interval before the next normal beat. A SLS sequence occurs if a second VPB occurs after this \"long\" interval. Such events produce changes in both the activation sequences and refractory periods of ventricular myocardium and the His-Purkinje system, and these alterations increase vulnerability to the onset of VT and VF.",
"   </p>",
"   <p>",
"    Normal single and dual chamber pacing can create SLS sequences that trigger VT or VF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Such events can occur in a variety of settings, usually due to the response of pacemaker algorithms to atrial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular ectopy. The incidence of SLS induced VT or VF in pacemaker patients is unknown, but is rarely recognized clinically. In the cohort of implantable cardioverter-defibrillator (ICD) patients discussed below, pacemaker facilitated ventricular arrhythmias occurred in 1 to 4 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/44\">",
"     44",
"    </a>",
"    ]. Because these patients were already known to be at high risk for such arrhythmias, the incidence in the general population of pacemaker patients is probably substantially lower.",
"   </p>",
"   <p>",
"    Pacing algorithms that maximize native conduction and minimize ventricular pacing can allow relatively long ventricular pauses. Thus, it can be theorized that these pacing modalities may increase the risk of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Functional single chamber atrial pacing'",
"    </a>",
"    above.) However, such an increased risk was not shown in a retrospective analysis of 1055 patients from two large ICD trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/44\">",
"     44",
"    </a>",
"    ]. Among patients whose devices were programmed DDD, VVI, and managed ventricular pacing modes, VT and VF episodes associated with pacemaker-facilitated SLS sequences occurred in 5.2, 3.3, and 2.6 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link&amp;anchor=H13#H13\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Modes to minimize ventricular pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because a ventricular pause is central to the SLS sequence, pacing strategies that minimize such pauses have been proposed as a method for reducing the risk of ventricular arrhythmias. However, such approaches have not proven successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/43,46\">",
"     43,46",
"    </a>",
"    ]. This failure appears to be due to the relatively short pauses (eg, &lt;1 second), and small changes in cycle length (eg, 40 to 200 msec) that are required to trigger ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38295/abstract/44,47\">",
"     44,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90108093\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an unexpected rhythm is observed in a patient with a dual-chamber pacing system, applying the following questions should provide a basis to understanding and managing unexpected rhythms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the pacing system functioning normally or not?",
"     </li>",
"     <li>",
"      Is the unexpected rhythm initiated by the pacemaker, mediated by the pacemaker, or a result of a specific pacing algorithm?",
"     </li>",
"     <li>",
"      To fully appreciate the variations that can occur as a result of company specific algorithms, is the provider aware of any algorithms that are programmed \"on\" and thoroughly understand how these algorithms function?",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/1\">",
"      Levine PA, Venditti FJ, Podrid PJ, Klein MD. Therapeutic and diagnostic benefits of intentional crosstalk mediated ventricular output inhibition. Pacing Clin Electrophysiol 1988; 11:1194.",
"     </a>",
"    </li>",
"    <li>",
"     Levine PA, Mace RC. Assessment and management of crosstalk. In: Pacing Therapy: A Guide to Cardiac Pacing for Optimal Hemodynamic Benefit, Futura, Mount Kisco, NY 1983. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/3\">",
"      Combs WJ, Reynolds DW, Sharma AD, Bennett TD. Cross-talk in bipolar pacemakers. Pacing Clin Electrophysiol 1989; 12:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/4\">",
"      Levine PA. Normal and abnormal rhythms associated with dual-chamber pacemakers. Cardiol Clin 1985; 3:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/5\">",
"      Bognolo D, Vijayanagar R, Eckstein P, et al. Fluctuations of the atrial cycle length and A-V delay with a universal (DDD) pacemaker. Clin Cardiol 1984; 7:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/6\">",
"      Barold SS, Belott PH. Behavior of the ventricular triggering period of DDD pacemakers. Pacing Clin Electrophysiol 1987; 10:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/7\">",
"      Stroobandt RX, Barold SS, Vandenbulcke FD, et al. A reappraisal of pacemaker timing cycles pertaining to automatic mode switching. J Interv Card Electrophysiol 2001; 5:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/8\">",
"      Bilitch M, Cosby RS, Cafferky EA. Ventricular fibrillation and competitive pacing. N Engl J Med 1967; 276:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/9\">",
"      Furman S, Cooper JA. Atrial fibrillation during A-V sequential pacing. Pacing Clin Electrophysiol 1982; 5:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/10\">",
"      Luceri RM, Ramirez AV, Castellanos A, et al. Ventricular tachycardia produced by a normally functioning AV sequential demand (DVI) pacemaker with \"committed\" ventricular stimulation. J Am Coll Cardiol 1983; 1:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/11\">",
"      Bayer R, Levine C, Murray TH. Guidelines for Confidentiality in Research on AIDS. AIDS Res 1983-1984; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/12\">",
"      Greenspon AJ, Greenberg RM, Frankl WS. Tracking of atrial flutter during DDD pacing: another form of pacemaker-mediated tachycardia. Pacing Clin Electrophysiol 1984; 7:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/13\">",
"      Frumin H, Furman S. Endless loop tachycardia started by an atrial premature complex in a patient with a dual chamber pacemaker. J Am Coll Cardiol 1985; 5:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/14\">",
"      Rozanski JJ, Blankstein RL, Lister JW. Pacer arrhythmias: myopotential triggering of pacemaker mediated tachycardia. Pacing Clin Electrophysiol 1983; 6:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/15\">",
"      Ausubel K, Gabry MD, Klementowicz PT, Furman S. Pacemaker-mediated endless loop tachycardia at rates below the upper rate limit. Am J Cardiol 1988; 61:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/16\">",
"      Barold SS, Falkoff MD, Ong LS, Heinle RA. Paradoxical induction of endless loop tachycardia by magnet application over a DDD pacemaker. Pacing Clin Electrophysiol 1986; 9:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/17\">",
"      den Dulk K, Lindemans FW, Wellens HJ. Noninvasive evaluation of pacemaker circus movement tachycardias. Am J Cardiol 1984; 53:537.",
"     </a>",
"    </li>",
"    <li>",
"     Levine PA, Selznick L. Prospective management of the patient with retrograde ventriculoatrial conduction: prevention and management of pacemaker mediated endless loop tachycardias, Siemens Pacesetter, Sylmar, CA 1990. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/19\">",
"      van Gelder LM, el Gamal MI, Baker R, Sanders RS. Tachycardia-termination algorithm: a valuable feature for interruption of pacemaker-mediated tachycardia. Pacing Clin Electrophysiol 1984; 7:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/20\">",
"      Duncan JL, Clark MF. Prevention and termination of pacemaker-mediated tachycardia in a new DDD pacing system (Siemens-Pacesetter model 2010T). Pacing Clin Electrophysiol 1988; 11:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/21\">",
"      Lamaison D, Girodo S, Limousin M. A new algorithm for a high level of protection against pacemaker-mediated tachycardia. Pacing Clin Electrophysiol 1988; 11:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/22\">",
"      Van Gelder BM, Bracke FA, Meijer A. Pacemaker-mediated tachycardia in a biventricular pacing system. Pacing Clin Electrophysiol 2001; 24:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/23\">",
"      Barold SS, Byrd CL. Cross-ventricular endless loop tachycardia during biventricular pacing. Pacing Clin Electrophysiol 2001; 24:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/24\">",
"      Levine PA. Postventricular atrial refractory periods and pacemaker mediated tachycardias. Clin Prog Pacing Electrophysiol1983; 1:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/25\">",
"      Barold SS. Management of patients with dual chamber pulse generators: central role of the pacemaker atrial refractory period. Learn Center Highlights 1990; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/26\">",
"      Satler LF, Rackley CE, Pearle DL, et al. Inhibition of a physiologic pacing system due to its anti-pacemaker-mediated tachycardia mode. Pacing Clin Electrophysiol 1985; 8:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/27\">",
"      Klementowicz PT, Furman S. Selective atrial sensing in dual chamber pacemakers eliminates endless loop tachycardia. J Am Coll Cardiol 1986; 7:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/28\">",
"      Pannizzo F, Amikam S, Bagwell P, Furman S. Discrimination of antegrade and retrograde atrial depolarization by electrogram analysis. Am Heart J 1986; 112:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/29\">",
"      Bricker JT, Ward KA, Zinner A, Gillette PC. Decrease in canine endocardial and epicardial electrogram voltages with exercise: implications for pacemaker sensing. Pacing Clin Electrophysiol 1988; 11:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/30\">",
"      Fr&ouml;hlig G, Schwerdt H, Schieffer H, Bette L. Atrial signal variations and pacemaker malsensing during exercise: a study in the time and frequency domain. J Am Coll Cardiol 1988; 11:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/31\">",
"      Barold SS, Levine PA. Pacemaker repetitive nonreentrant ventriculoatrial synchronous rhythm. A review. J Interv Card Electrophysiol 2001; 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/32\">",
"      Chien WW, Foster E, Phillips B, et al. Pacemaker syndrome in a patient with DDD pacemaker for long QT syndrome. Pacing Clin Electrophysiol 1991; 14:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/33\">",
"      Nielsen JC, Kristensen L, Andersen HR, et al. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol 2003; 42:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/34\">",
"      Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/35\">",
"      Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/36\">",
"      O'Keefe JH Jr, Abuissa H, Jones PG, et al. Effect of chronic right ventricular apical pacing on left ventricular function. Am J Cardiol 2005; 95:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/37\">",
"      Shukla HH, Hellkamp AS, James EA, et al. Heart failure hospitalization is more common in pacemaker patients with sinus node dysfunction and a prolonged paced QRS duration. Heart Rhythm 2005; 2:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/38\">",
"      Melzer C, Sowelam S, Sheldon TJ, et al. Reduction of right ventricular pacing in patients with sinus node dysfunction using an enhanced search AV algorithm. Pacing Clin Electrophysiol 2005; 28:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/39\">",
"      Dennis MJ, Sparks PB. Pacemaker mediated tachycardia as a complication of the autointrinsic conduction search function. Pacing Clin Electrophysiol 2004; 27:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/40\">",
"      Levine PA. First reported case where a PMT was repeatedly triggered by the AV. Pacing Clin Electrophysiol 2004; 27:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/41\">",
"      Sweeney MO, Ellenbogen KA, Casavant D, et al. Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs. J Cardiovasc Electrophysiol 2005; 16:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/42\">",
"      Savour&eacute; A, Fr&ouml;hlig G, Galley D, et al. A new dual-chamber pacing mode to minimize ventricular pacing. Pacing Clin Electrophysiol 2005; 28 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/43\">",
"      Himmrich E, Przibille O, Zellerhoff C, et al. Proarrhythmic effect of pacemaker stimulation in patients with implanted cardioverter-defibrillators. Circulation 2003; 108:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/44\">",
"      Sweeney MO, Ruetz LL, Belk P, et al. Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007; 50:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/45\">",
"      van Mechelen R, Schoonderwoerd R. Risk of managed ventricular pacing in a patient with heart block. Heart Rhythm 2006; 3:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/46\">",
"      Friedman PA, Jalal S, Kaufman S, et al. Effects of a rate smoothing algorithm for prevention of ventricular arrhythmias: results of the Ventricular Arrhythmia Suppression Trial (VAST). Heart Rhythm 2006; 3:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38295/abstract/47\">",
"      Viskin S, Fish R, Zeltser D, et al. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? Heart 2000; 83:661.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1037 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38295=[""].join("\n");
var outline_f37_25_38295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90108093\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      UNEXPECTED RHYTHMS WITH NORMALLY FUNCTIONING DUAL-CHAMBER PACING SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Crosstalk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inappropriate automatic mode switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pacemaker-initiated tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pacemaker-mediated tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tracking of a native atrial tachyarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Endless loop tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Management of an endless loop tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Repetitive non-reentrant ventriculoatrial synchronous rhythms (AV desynchronization arrhythmia)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Functional single chamber atrial pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Long programmed AV delay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - AV/PV hysteresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - AAI/DDD pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VENTRICULAR ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90108093\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1037|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?1/32/1539\" title=\"waveform 1\">",
"      ECG Managed ventricular pacing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38296="Sudden sensorineural hearing loss";
var content_f37_25_38296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sudden sensorineural hearing loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38296/contributors\">",
"     Peter C Weber, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38296/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38296/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38296/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/25/38296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden sensorineural hearing loss (SSNHL) involves an acute unexplained hearing loss, nearly always unilateral, that occurs over less than a 72 hour period. Most cases are idiopathic, and the prognosis depends on the severity of the hearing loss.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of SSNHL are discussed here. The evaluation of non-acute hearing loss and the differential diagnosis of hearing loss are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of sudden sensorineural hearing loss (SSNHL) is uncertain. Since recovery is often spontaneous, many affected people likely never seek medical attention. Estimates of incidence typically range from 2 to 20 per 100,000 people per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. SSNHL can occur at any age, but most commonly affects patients 43 to 53 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for idiopathic SSNHL are uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/5\">",
"     5",
"    </a>",
"    ]. Similar numbers of men and women are affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1\">",
"     1",
"    </a>",
"    ]. Compared with patients with unilateral SSNHL, those with bilateral SSNHL are more likely to be older, have cardiovascular disease, and have a positive antinuclear antibody titer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1\">",
"     1",
"    </a>",
"    ]. Some studies suggest a relationship between dietary intake of nutrients and risk of SSNHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSNHL may be a risk factor for stroke. In a study of patients in Taiwan hospitalized for treatment of a first episode of SSNHL, the risk of stroke over a five year follow-up period was increased compared to patients of similar age and demographics hospitalized for appendicitis (HR 1.64, 95% CI 1.31-2.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/7\">",
"     7",
"    </a>",
"    ]. In a review of the literature, the committee developing 2012 guidelines for the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) found that the relationship between SSNHL and risk of stroke did not meet their threshold for significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have an acute onset of hearing loss, in whom examination reveals sensorineural hearing loss (SSNHL) with no underlying condition identifiable by history or examination, are considered to have SSNHL.",
"   </p>",
"   <p>",
"    The US National Institute for Deafness and Communication Disorders (NICDC) specifies the following criteria for the diagnosis of SSNHL: idiopathic hearing loss of at least 30 dB over at least three test frequencies occurring over a 72-hour period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/8\">",
"     8",
"    </a>",
"    ]. This definition was adopted for the 2012 AAO-HNS practice guideline for SSNHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ] and is the one most often used in randomized trials. The definition assumes that hearing was either normal or any loss was stable before the onset of new symptoms. Many studies, however, use differing criteria for identifying SSNHL, including loss of 10 to 20 dB in two or three frequencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] or hearing loss within 12 hours, including hearing loss noted on awakening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of most cases of sudden sensorineural hearing loss (SSNHL) is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/12\">",
"     12",
"    </a>",
"    ]. Postulated causes for idiopathic SSNHL include viral cochleitis, microvascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/13\">",
"     13",
"    </a>",
"    ], and autoimmune disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. An association of genes related to prothrombotic states (particularly MTHFR polymorphisms) and increased serum levels of fibrinogen and homocysteine in patients with SSNHL suggests a multifactorial basis for microvascular events as one cause of SSNHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpes simplex type I virus (HSV-I) may be a significant etiologic factor in SSNHL, analogous to its possible role in Bell's palsy. Other etiologies of SSNHL are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78516 \" href=\"mobipreview.htm?8/37/8796\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=see_link&amp;anchor=H3#H3\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Epidemiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sudden sensorineural hearing loss (SSNHL) typically report immediate or rapid hearing loss, or find that they have lost hearing upon awakening. In a series of 56 patients, 28 had sudden hearing loss, 27 noted hearing loss on awakening, and one had rapidly progressive hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/9\">",
"     9",
"    </a>",
"    ]. Most patients have unilateral hearing loss, but up to 3 percent of cases may be bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with unilateral SSNHL can occasionally develop SSNHL in the other ear.",
"   </p>",
"   <p>",
"    Many patients, however, present with a sensation of a blocked or full ear and do not recognize that they have lost hearing. Because a blocked ear is common, and can be attributed to a number of conditions that are not serious, patients may not seek immediate attention for this symptom, and clinicians may not be sufficiently concerned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 90 percent of patients with unilateral SSNHL report tinnitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The tinnitus is often difficult to treat and greatly impacts the psychological burden of SSNHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25495?source=see_link\">",
"     \"Treatment of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vertigo has been reported in 20 to 60 percent of patients with SSNHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients occasionally report ear pain or paresthesias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination should not reveal signs of otitis media or obstruction in the ear canal and, except for signs related to hearing loss, should be otherwise unremarkable. Evaluation for vertebral artery dissection should be considered in patients with occipital or posterior neck pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSNHL may have a profound impact on quality of life, which is further impaired if there is significant associated dizziness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tinnitus. For patients with unilateral hearing loss, difficulty in localizing sound may increase the risk of accidents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7188815\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have an acute onset of hearing loss, in whom examination reveals sensorineural hearing loss with no underlying condition identifiable by history or examination, are considered to have sudden sensorineural hearing loss (SSNHL). Patients who complain of sudden hearing loss or awaken with new hearing loss should be evaluated to determine if the hearing deficit is due to a conductive or sensorineural problem. If initial assessment takes place over the telephone, the patient can be told to hum and asked if the sound seems to lateralize to one side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/4\">",
"     4",
"    </a>",
"    ]. Lateralization to the side of hearing loss suggests conductive loss, which does not require emergency evaluation. Although both conductive and sensorineural hearing loss require evaluation, there is more urgency to initiate treatment when SSNHL is suspected. In the office, sensorineural and conductive loss can be distinguished by the Weber and Rinne tests (",
"    <a class=\"graphic graphic_figure graphicRef58032 \" href=\"mobipreview.htm?40/5/41043\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be asked about a history of trauma, ear pain, ear drainage, fever, focal neurologic symptoms, headache, diplopia, recent eye pain or redness, and prior history of hearing loss. A history of fluctuating hearing loss should suggest another diagnosis, such as Meniere disease, hyperviscosity syndrome, or autoimmune disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=see_link\">",
"     \"Meniere disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12968?source=see_link\">",
"     \"Cogan&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination should include otoscopic examination to exclude otitis media, foreign bodies, perforated tympanic membrane, otitis externa, or cholesteatoma. If present, impacted cerumen should be removed and the hearing loss evaluated thereafter. A neurologic examination is necessary to exclude stroke in the territory of the anterior inferior cerebellar artery as a cause of the sudden hearing loss. (See",
"    <a class=\"local\" href=\"#H7189043\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients with sudden SSNHL should undergo audiometric evaluation and most patients should undergo MRI scanning with gadolinium unless the etiology is absolutely clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Accurate audiometric evaluation is essential both to support the initial diagnosis and to follow-up changes over time.",
"   </p>",
"   <p>",
"    Routine blood tests are not indicated in the evaluation of a patient with SSNHL. Laboratory studies should be based on findings from the history and physical examination that suggest a specific etiology that warrants diagnostic studies. As an example, Lyme titers may be indicated in patients with a history suggesting exposure in an endemic area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7189167\">",
"    <span class=\"h2\">",
"     MRI scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected SSNHL should be imaged with contrast MRI, whenever possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ]. CT scan does not provide sufficient resolution for detecting tumors of the cerebellopontine angle or small brainstem infarctions and should be used only in patients who cannot undergo MR scanning.",
"   </p>",
"   <p>",
"    Most patients with SSNHL likely have a viral, autoimmune, or microvascular etiology, and these conditions will not be identifiable by MRI. However, other causes of unilateral hearing loss, such as acoustic neuroma, perilymphatic fistula, Meniere disease, vascular insufficiency, multiple sclerosis, or other conditions involving the central nervous system may only be discovered on MRI scan.",
"   </p>",
"   <p>",
"    In a series of 82 patients who were seen at a tertiary referral center with SSNHL, MRI revealed the etiology of hearing loss in six patients (four with acoustic neuroma; one with changes in the pons; one with internal carotid artery occlusion), and a possible etiology of SSNHL was found in six additional patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/19\">",
"     19",
"    </a>",
"    ]. In another series of 556 patients, 17 patients (3 percent) had a retrocochlear tumor (schwannoma, neurofibroma, or undifferentiated carcinoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/21\">",
"     21",
"    </a>",
"    ]. Thirty of the 556 patients had mid-frequency hearing loss, and 10 of those patients (33 percent) had a retrocochlear tumor. Other studies report the rate of vestibular schwannomas to range from 2.7 to 10.2 percent in patients presenting with sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatives to MRI for the diagnosis of a vestibular schwannoma are an auditory brainstem response or audiometric follow-up, but they are not as sensitive as an MRI and would not identify other potential causes of hearing loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link&amp;anchor=H7#H7\">",
"     \"Vestibular schwannoma (acoustic neuroma)\", section on 'Audiometry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link&amp;anchor=H9#H9\">",
"     \"Vestibular schwannoma (acoustic neuroma)\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7189043\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple causes of conductive and sensorineural hearing loss (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"mobipreview.htm?4/62/5101\">",
"     table 2",
"    </a>",
"    ). Typically, SSNHL is distinguished from other causes of sensorineural hearing loss because most other etiologies result in bilateral hearing loss, and sudden onset is infrequent.",
"   </p>",
"   <p>",
"    The most common cause of unilateral sudden hearing loss that should be distinguished from SSNHL is an acute stroke, typically due to occlusion of the anterior inferior cerebellar artery (AICA), which feeds the internal auditory artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ]. AICA occlusion may manifest as ipsilateral Horner syndrome, diplopia, nystagmus, facial weakness, limb clumsiness, ataxia, and contralateral loss of pain or temperature sensation. Less frequent neurologic causes of sensorineural hearing loss include multiple sclerosis, meningitis, vestibular schwannomas, and migrainous infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=see_link\">",
"     \"Headache, migraine, and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strong evidence for the efficacy of any treatment option for patients with sudden sensorineural hearing loss (SSNHL) is not available. Glucocorticoids are considered first-line therapy for SSNHL and may be administered systemically (generally orally) or locally via intratympanic installation. Intratympanic glucocorticoids are often reserved for use when hearing does not improve after a trial of systemic therapy. Intratympanic glucocorticoids can also be used as initial therapy in patients in whom high-dose systemic glucocorticoids should be avoided, such as in patients with diabetes. In addition to glucocorticoids, we suggest treatment with an antiviral agent for treatment of possible HSV-1 infection, although others believe such treatment is not indicated. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Antiviral agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Management strategies vary, reflecting the uncertainty of treatment efficacy and the significant rate of spontaneous recovery. One survey found that glucocorticoids were used more often by otolaryngologists than general practitioners who treat patients with SSNHL (98 percent and 73 percent, respectively) and used in higher doses by specialists (at least 60 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/22\">",
"     22",
"    </a>",
"    ]. Additionally, approximately 50 percent of otolaryngologists treated patients with antiviral therapy, compared to 16 percent of generalists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;While oral glucocorticoids have been considered standard therapy for SSNHL, the benefit of these drugs is unclear. Two systematic reviews and a meta-analysis identified only two randomized studies of sufficient quality for analysis, and these studies differed in their conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/11,23,24\">",
"     11,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study from 1980 evaluated 67 patients with SSNHL within 10 days of hearing loss at two centers and demonstrated some benefit from glucocorticoid treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients were randomly assigned to placebo or oral glucocorticoids (regimens differed at the two centers). More patients treated with glucocorticoids recovered hearing (61 versus 32 percent, relative risk [RR] 1.30, 95% CI 0.91-1.86). Patients with mild hearing loss recovered hearing, regardless of treatment group. Glucocorticoid therapy did not appear to improve rates of recovery compared with placebo in 23 patients with profound hearing loss (18 versus 17 percent). A subgroup analysis of patients with moderate hearing loss found the recovery rate for the glucocorticoid group was 78 percent, compared to 38 percent for the placebo group (RR 1.74, 95% CI 1.19-2.55).",
"      <br/>",
"      <br/>",
"      Although issues related to randomization, concealment, and differing treatment protocols call into question the significance of these findings, the study remains the best effort at evaluating the efficacy of glucocorticoids for SSNHL.",
"     </li>",
"     <li>",
"      A randomized study from 2001, evaluating the effectiveness of glucocorticoids or carbogen inhalation therapy in 41 patients with SSNHL found no difference in hearing level at six different frequencies between the glucocorticoid- and placebo-treated patients; improvement was found in 60 and 63 percent at early follow-up (RR 0.94) and 80 and 81 percent at late follow-up (RR 0.98) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/26\">",
"       26",
"      </a>",
"      ]. Because a relatively small number of patients were randomly assigned to four treatment groups, the groups may have been too small to detect statistically-significant differences in outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The systematic reviews conclude that the effectiveness of glucocorticoids remains unproven. Results of the meta-analysis that pooled data from the two RCTs showed no difference between treatment groups (OR 2.47; 95% CI 0.89-6.84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of audiometry outcome and word recognition scores, comparing patients treated with glucocorticoids to those who declined treatment, found a significant improvement in the treated group who initially had severe to profound loss; no difference was seen when milder cases were included in the analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/27\">",
"     27",
"    </a>",
"    ]. Another retrospective review found patients who were treated within two weeks of symptoms with at least 60 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily did better than patients who received lower doses of glucocorticoid, or who were treated later in their course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/28\">",
"     28",
"    </a>",
"    ]. In a prospective randomized study, high-dose pulse therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (300 mg daily for three days) was not more effective than prednisone 70 mg on day one with tapered dose over seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With recognition of the equivocal efficacy of treatment, guidelines from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) suggest that patients with SSNHL be offered treatment with oral glucocorticoids, with the greatest likelihood of some response if started promptly after diagnosis, and within two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients should be advised of the risks and benefits of glucocorticoid treatment. The recommended dose for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (to 60 mg maximum) given as a single dose for 10 to 14 days. Some have advised that treatment be extended another 10 days if a partial response is found at the end of the initial course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78218348\">",
"    <span class=\"h2\">",
"     Intratympanic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratympanic glucocorticoids have been used for the treatment of SSNHL primarily for patients who are refractory to initial oral glucocorticoids, but have also been studied for initial treatment both with and without oral glucocorticoids. We suggest that patients who do not improve with 10 days of oral glucocorticoids receive intratympanic glucocorticoid injection. Patients who are intolerant of oral glucocorticoids (including patients with diabetes and those sensitive to side effects) are appropriately initially managed with intratympanic steroid administration.",
"   </p>",
"   <p>",
"    Dosing regimens for intratympanic glucocorticoids vary between studies, but include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    10 to 24",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    30 to 40",
"    <span class=\"nowrap\">",
"     mg/mL;",
"    </span>",
"    dosing frequency ranges from a few times a day through a pressure-equalizing tube to several days consecutively or once weekly. Intratympanic administration is typically managed by an otolaryngologist. Transient side effects associated with intratympanic dexamethasone included otalgia, dizziness, and ear fullness.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of several small, prospective cohort studies and randomized trials found that intratympanic glucocorticoid therapy following failed oral glucocorticoids was associated with a modest, statistically-significant improvement in hearing (13.3 dB, 95% CI 7.7-18.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/31\">",
"     31",
"    </a>",
"    ]. Nearly all studies found some degree of benefit, but it is unclear if this represents a clinically-significant improvement in hearing. While awaiting more definitive evidence from additional trials, we suggest that patients who do not improve with 10 days of oral glucocorticoids receive intratympanic glucocorticoids injection.",
"   </p>",
"   <p>",
"    A randomized trial comparing intratympanic (IT)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    delivered as 4 doses over 14 days) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 mg orally for 14 days with a 5-day taper) in 250 patients with SSNHL seen within 14 days of onset found that IT was non inferior to oral steroids when hearing loss was assessed at two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/32\">",
"     32",
"    </a>",
"    ]. Guidelines from the AAO-HNS suggest that the choice or oral or IT glucocorticoids as initial therapy be based upon considerations such as cost and side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ]; IT glucocorticoids are a reasonable alternative for patient with diabetes and others who may not tolerate high-dose systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simultaneous administration of intratympanic and oral glucocorticoids as initial treatment does not appear to offer additional benefit. In a randomized trial of 88 patients with SSNHL, there was no difference in hearing recovery between those assigned to simultaneous intratympanic and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    versus oral dexamethasone followed by intratympanic dexamethasone for patients who did not improve with initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/34\">",
"     34",
"    </a>",
"    ]. Fifteen of 44 patients in the latter treatment arm avoided intratympanic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antiviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HSV-I may be an important etiology for SSNHL, randomized trials have found no superiority of treatment with antiviral medication plus glucocorticoids compared with glucocorticoids alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. However, these studies were small and associated with some flaws and, therefore, definitive conclusions cannot be made.",
"   </p>",
"   <p>",
"    Guidelines from the AAO-HNS suggest not treating with antivirals, citing the lack of evidence for efficacy and some risk of medication side effects (nausea, vomiting, dizziness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"     3",
"    </a>",
"    ]. A systematic analysis of randomized trials evaluating antiviral agents for SSNHL noted no difference in response rates for groups that used antivirals or not, but also no difference in serious adverse effects between groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/39\">",
"     39",
"    </a>",
"    ]. The review concluded that larger trials, with a uniform definition of SSNHL, are needed to draw definitive conclusions on the effectiveness of antivirals for this condition. In the absence of larger trials of antivirals, we typically treat SSNHL of unknown origin with a 7- to 10-day course of an anti-HSV antiviral such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    1 g three times daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    500 mg three times daily, in addition to high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many therapies have been evaluated, with studies hindered by varying definitions of recovery and small sample sizes. Some effectiveness has been suggested for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apheresis of fibrinogen and low density lipoprotein (LDL) &mdash; A randomized trial compared a single apheresis of fibrinogen and low-density lipoprotein (LDL) to a glucocorticoid regimen (daily infusion with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , hydroxyethyl starch, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/40\">",
"       40",
"      </a>",
"      ]. Improvement in patients who received apheresis appeared to be at least comparable to outcomes with the standard regimen. In a subsequent randomized trial, those receiving apheresis plus a glucocorticoid regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and glycerol) showed improved hearing recovery at 10 days compared to those receiving the glucocorticoid regimen alone (76 versus 45 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral magnesium &mdash; In a small trial (n = 28), patients randomly assigned to magnesium plus glucocorticoid demonstrated greater mean improvement in hearing across all frequencies compared to patients receiving placebo plus glucocorticoid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/42\">",
"       42",
"      </a>",
"      ]. In another trial, patients randomly assigned to magnesium plus carbogen had greater recovery than those treated with carbogen alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Zinc, like magnesium, may provide some synergistic effect with glucocorticoids. In a small trial (n=66), patients randomly assigned to zinc plus glucocorticoid treatment had improved hearing gain compared to glucocorticoid treatment alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperbaric oxygen &mdash; A systematic review concluded that hyperbaric oxygen therapy may be of some benefit when administered early in the course of SSNHL, although the clinical significance of the benefit was unclear and the underlying studies had methodologic shortcomings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/45\">",
"       45",
"      </a>",
"      ]. In one institution, patients seen between 2002 and 2009 were treated with intravenous glucocorticoids and hyperbaric oxygen, and those seen between 2009 and 2011 were treated with systemic plus intratympanic glucocorticoids; patients who received intratympanic steroids were more likely to recover hearing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous Hypaque and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      , which changes the endocochlear potential, may have a limited treatment role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tympanotomy and sealing of the round window membrane may be helpful in cases of acute SSNHL where glucocorticoid treatment is ineffective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These therapies require further evaluation before they can be recommended.",
"   </p>",
"   <p>",
"    Agents to improve cochlear blood flow and oxygen delivery have been considered, including carbogen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , ginkgo biloba,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , carbogen, and prostaglandin E1 but have not proven to be of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/20,48-52\">",
"     20,48-52",
"    </a>",
"    ]. Histamine and bed rest are also not effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/20\">",
"     20",
"    </a>",
"    ]. Some advise treatment with a low sodium diet and diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the hearing does not return, even after treatment, then management of the hearing loss with assistive devices is indicated, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for sudden sensorineural hearing loss (SSNHL) is reasonably good, especially if it is a high- or low-frequency hearing loss pattern and not flat across all frequencies. The prognosis is poor in patients with profound hearing loss across all frequencies: approximately three-quarters of such patients have no recovery of hearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who recovered at least partially, 54.5 percent showed improvement within 10 days, and only 1 of 156 patients showed any recovery beyond six months in one cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients who have not improved within three months will generally not recover significantly.",
"   </p>",
"   <p>",
"    Approximately two-thirds of patients with idiopathic SSNHL will experience recovery, although this recovery is often not complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Prognosis is worse in patients who are older and may be worse in those with vertigo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], although this is not a consistent finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38296/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78218479\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up audiogram should be obtained within six months of the initial diagnosis. Earlier audiometric follow-up may be indicated to assess the benefit of early treatment, if it has been initiated, and to determine if salvage therapy is indicated.",
"   </p>",
"   <p>",
"    Auditory rehabilitation may be required for patients with permanent hearing loss. Assistive hearing devices should be discussed for patients with residual hearing loss. These modalities are dependent on the level of loss. The solutions range from traditional hearing aids to cochlear implants or Baha for those with severe to profound loss in that one ear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/20/44353?source=see_link\">",
"       \"Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden sensorineural hearing loss (SSNHL) is hearing loss that occurs acutely, usually within 12 hours of onset, and is unilateral in 90 percent of cases. The hearing loss may occur suddenly, be found on awakening, or may be rapidly progressive over hours (or perhaps over two to three days). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many etiologies for SSNHL (",
"      <a class=\"graphic graphic_table graphicRef78516 \" href=\"mobipreview.htm?8/37/8796\">",
"       table 1",
"      </a>",
"      ); however, for many cases a definite cause is not known. Most of these cases are felt to be due to viral cochleitis, a microvascular event, or an autoimmune process. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spontaneous improvement is common for SSNHL, and studies are contradictory on the effectiveness of glucocorticoid therapy. We suggest initial treatment with a 10- to 14-day course of high-dose glucocorticoids (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 60 per day) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Intratympanic glucocorticoids may be used as initial therapy for patients intolerant to high-dose steroids. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Oral glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H78218348\">",
"       'Intratympanic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials have not demonstrated effectiveness for the addition of antiviral therapy to glucocorticoid protocols. However, a subset of patients with SSNHL may have HSV-I infection and could benefit from antiviral drugs. In weighing the potential benefits of antiviral treatment for this unidentifiable subset (despite lack of effectiveness evidence from controlled trials) against the safety and minimal toxicity of antiviral therapy, we suggest treatment for 7 to 10 days with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      1 gram three times a day or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      500 mg three times a day (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antiviral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a trial of intratympanic corticosteroids for patients who do not show improvement after 10 days of oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H78218348\">",
"       'Intratympanic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately two-thirds of patients with SSNHL will experience recovery, although this recovery is often not complete. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/1\">",
"      Fetterman BL, Luxford WM, Saunders JE. Sudden bilateral sensorineural hearing loss. Laryngoscope 1996; 106:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/2\">",
"      Hughes GB, Freedman MA, Haberkamp TJ, Guay ME. Sudden sensorineural hearing loss. Otolaryngol Clin North Am 1996; 29:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/3\">",
"      Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012; 146:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/4\">",
"      Rauch SD. Clinical practice. Idiopathic sudden sensorineural hearing loss. N Engl J Med 2008; 359:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/5\">",
"      Nakashima T, Tanabe T, Yanagita N, et al. Risk factors for sudden deafness: a case-control study. Auris Nasus Larynx 1997; 24:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/6\">",
"      Cadoni G, Agostino S, Scipione S, Galli J. Low serum folate levels: a risk factor for sudden sensorineural hearing loss? Acta Otolaryngol 2004; 124:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/7\">",
"      Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study. Stroke 2008; 39:2744.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute of Health. Sudden Deafness. Bethesda, MD. National Institutes of Health; 2000. NIH publication 00-4757.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/9\">",
"      Yimtae K, Srirompotong S, Kraitrakul S. Idiopathic sudden sensorineural hearing loss. J Med Assoc Thai 2001; 84:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/10\">",
"      Ho HG, Lin HC, Shu MT, et al. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 2004; 114:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/11\">",
"      Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: I. A systematic review. Arch Otolaryngol Head Neck Surg 2007; 133:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/12\">",
"      Chau JK, Lin JR, Atashband S, et al. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope 2010; 120:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/13\">",
"      Yueh B, Shapiro N, MacLean CH, Shekelle PG. Screening and management of adult hearing loss in primary care: scientific review. JAMA 2003; 289:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/14\">",
"      Toubi E, Ben-David J, Kessel A, et al. Immune-mediated disorders associated with idiopathic sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 2004; 113:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/15\">",
"      Baek MJ, Park HM, Johnson JM, et al. Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss. J Immunol 2006; 177:4203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/16\">",
"      Capaccio P, Ottaviani F, Cuccarini V, et al. Genetic and acquired prothrombotic risk factors and sudden hearing loss. Laryngoscope 2007; 117:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/17\">",
"      Rambold H, Boenki J, Stritzke G, et al. Differential vestibular dysfunction in sudden unilateral hearing loss. Neurology 2005; 64:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/18\">",
"      Sauvaget E, Kici S, Petelle B, et al. Vertebrobasilar occlusive disorders presenting as sudden sensorineural hearing loss. Laryngoscope 2004; 114:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/19\">",
"      Weber PC, Zbar RI, Gantz BJ. Appropriateness of magnetic resonance imaging in sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 1997; 116:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/20\">",
"      Grandis JR, Hirsch BE, Wagener MM. Treatment of idiopathic sudden sensorineural hearing loss. Am J Otol 1993; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/21\">",
"      Lin YT, Young YH. Retrocochlear mass lesion in mid-frequency sudden deafness. Otolaryngol Head Neck Surg 2008; 138:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/22\">",
"      Shemirani NL, Schmidt M, Friedland DR. Sudden sensorineural hearing loss: an evaluation of treatment and management approaches by referring physicians. Otolaryngol Head Neck Surg 2009; 140:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/23\">",
"      Wei BP, Mubiru S, O'Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2006; :CD003998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/24\">",
"      Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: II. A Meta-analysis. Arch Otolaryngol Head Neck Surg 2007; 133:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/25\">",
"      Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol 1980; 106:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/26\">",
"      Cinamon U, Bendet E, Kronenberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study. Eur Arch Otorhinolaryngol 2001; 258:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/27\">",
"      Chen CY, Halpin C, Rauch SD. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol Neurotol 2003; 24:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/28\">",
"      Slattery WH, Fisher LM, Iqbal Z, Liu N. Oral steroid regimens for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005; 132:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/29\">",
"      Westerlaken BO, de Kleine E, van der Laan B, Albers F. The treatment of idiopathic sudden sensorineural hearing loss using pulse therapy: a prospective, randomized, double-blind clinical trial. Laryngoscope 2007; 117:684.",
"     </a>",
"    </li>",
"    <li>",
"     Arts HA. Sensorineural hearing loss: evaluation and management in adults. In: Cummings Otolaryngology Head and Neck Surgery, 4th ed, Elsevier Mosby, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/31\">",
"      Spear SA, Schwartz SR. Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngol Head Neck Surg 2011; 145:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/32\">",
"      Rauch SD, Halpin CF, Antonelli PJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011; 305:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/33\">",
"      Han CS, Park JR, Boo SH, et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg 2009; 141:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/34\">",
"      Park MK, Lee CK, Park KH, et al. Simultaneous versus subsequent intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2011; 145:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/35\">",
"      Stokroos RJ, Albers FW, Tenvergert EM. Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial. Acta Otolaryngol 1998; 118:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/36\">",
"      Uri N, Doweck I, Cohen-Kerem R, Greenberg E. Acyclovir in the treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2003; 128:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/37\">",
"      Tucci DL, Farmer JC Jr, Kitch RD, Witsell DL. Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol 2002; 23:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/38\">",
"      Westerlaken BO, Stokroos RJ, Dhooge IJ, et al. Treatment of idiopathic sudden sensorineural hearing loss with antiviral therapy: a prospective, randomized, double-blind clinical trial. Ann Otol Rhinol Laryngol 2003; 112:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/39\">",
"      Awad Z, Huins C, Pothier DD. Antivirals for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2012; 8:CD006987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/40\">",
"      Suckf&uuml;ll M, Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002; 360:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/41\">",
"      Bianchin G, Russi G, Romano N, Fioravanti P. Treatment with HELP-apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled study. Laryngoscope 2010; 120:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/42\">",
"      Nageris BI, Ulanovski D, Attias J. Magnesium treatment for sudden hearing loss. Ann Otol Rhinol Laryngol 2004; 113:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/43\">",
"      Gordin A, Goldenberg D, Golz A, et al. Magnesium: a new therapy for idiopathic sudden sensorineural hearing loss. Otol Neurotol 2002; 23:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/44\">",
"      Yang CH, Ko MT, Peng JP, Hwang CF. Zinc in the treatment of idiopathic sudden sensorineural hearing loss. Laryngoscope 2011; 121:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/45\">",
"      Bennett MH, Kertesz T, Yeung P. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev 2007; :CD004739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/46\">",
"      Suzuki H, Hashida K, Nguyen KH, et al. Efficacy of intratympanic steroid administration on idiopathic sudden sensorineural hearing loss in comparison with hyperbaric oxygen therapy. Laryngoscope 2012; 122:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/47\">",
"      Gedlicka C, Formanek M, Ehrenberger K. Analysis of 60 patients after tympanotomy and sealing of the round window membrane after acute unilateral sensorineural hearing loss. Am J Otolaryngol 2009; 30:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/48\">",
"      Labus J, Breil J, St&uuml;tzer H, Michel O. Meta-analysis for the effect of medical therapy vs. placebo on recovery of idiopathic sudden hearing loss. Laryngoscope 2010; 120:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/49\">",
"      Donaldson JA. Heparin therapy for sudden sensorineural hearing loss. Arch Otolaryngol 1979; 105:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/50\">",
"      Burschka MA, Hassan HA, Reineke T, et al. Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients. Eur Arch Otorhinolaryngol 2001; 258:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/51\">",
"      Kronenberg J, Almagor M, Bendet E, Kushnir D. Vasoactive therapy versus placebo in the treatment of sudden hearing loss: a double-blind clinical study. Laryngoscope 1992; 102:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/52\">",
"      Agarwal L, Pothier DD. Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2009; :CD003422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/53\">",
"      Yeo SW, Lee DH, Jun BC, et al. Hearing outcome of sudden sensorineural hearing loss: long-term follow-up. Otolaryngol Head Neck Surg 2007; 136:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/54\">",
"      Ben-David J, Luntz M, Magamsa I, et al. Tinnitus as a prognostic sign in idiopathic sudden sensorineural hearing loss. Int Tinnitus J 2001; 7:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/55\">",
"      Ben-David J, Luntz M, Podoshin L, et al. Vertigo as a prognostic sign in sudden sensorineural hearing loss. Int Tinnitus J 2002; 8:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38296/abstract/56\">",
"      Weng SF, Chen YS, Liu TC, et al. Prognostic factors of sudden sensorineural hearing loss in diabetic patients. Diabetes Care 2004; 27:2560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6847 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38296=[""].join("\n");
var outline_f37_25_38296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7188815\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7189167\">",
"      MRI scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7189043\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78218348\">",
"      Intratympanic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78218479\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6847|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/5/41043\" title=\"figure 1\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/37/8796\" title=\"table 1\">",
"      Sudden sensorineural loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/62/5101\" title=\"table 2\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12968?source=related_link\">",
"      Cogan&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/20/44353?source=related_link\">",
"      Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25495?source=related_link\">",
"      Treatment of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38297="Ifosfamide: Drug information";
var content_f37_25_38297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ifosfamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/46/19173?source=see_link\">",
"    see \"Ifosfamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/33/11800?source=see_link\">",
"    see \"Ifosfamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ifex",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ifex",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also consult details concerning dosing in combination regimens.",
"     <b>",
"      Note:",
"     </b>",
"     To prevent bladder toxicity, ifosfamide should be given with the urinary protector mesna and hydration of at least 2 L of oral or I.V. fluid per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. manufacturer&rsquo;s labeling; as part of combination chemotherapy and with mesna: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks or after hematologic recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VIP regimen: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for 4 cycles (in combination with etoposide, mesna, and cisplatin) (Nichols, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VeIP regimen: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for 4 cycles (in combination with vinblastine, mesna, and cisplatin) (Loehrer, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Soft tissue sarcoma, cervical cancer (advanced or recurrent), pancreatic cancer (relapsed or refractory):",
"     </b>",
"     I.V.: 2000-2400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 consecutive days (with mesna), may repeat after 3-4 weeks (or longer depending on patient status) or if lower daily dosage or total dosage over a longer time period is indicated, administer every other day (eg, days 1, 3, 5, 7, 9) or over 10 consecutive days at reduced doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High",
"     <b>",
"      single-dose",
"     </b>",
"     infusions of up to 5000-8000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /24 hour with continuous mesna may also be feasible; may repeat after 3-4 weeks (or longer depending on patient&rsquo;s condition).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adult unlabeled uses and/or dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TIP regimen (unlabeled dosing): 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days (days 2-5) every 3 weeks for 4 cycles (in combination with paclitaxel, mesna, and cisplatin) (Kondagunta, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TICE regimen (unlabeled dosing): 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days (days 2-4) over 4 hours every 2 weeks for 2 cycles (in combination with paclitaxel and mesna; followed by carboplatin and etoposide) (Kondagunta, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer, recurrent or metastatic:",
"     </b>",
"     I.V.:1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day for 5 days every 3 weeks (with mesna) (Coleman, 1986; Sutton, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, relapsed or refractory:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE regimen: 5000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (over 24 hours) beginning on day 2 every 2 weeks for 2 cycles (in combination with mesna, carboplatin, and etoposide) (Moskowitz, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IGEV regimen: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every 3 weeks for 4 cycles (in combination with mesna, gemcitabine, vinorelbine, and prednisolone) (Santoro, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MINE-ESHAP regimen: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 4 weeks for up to 2 cycles (MINE is combination with mesna, mitoxantrone, and etoposide; MINE alternates with ESHAP for up to 2 cycles of each) (Fernandez, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin lymphomas:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CODOX-M/IVAC regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults &le;65 years: Cycles 2 and 4 (IVAC): 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (IVAC is combination with cytarabine, mesna, and etoposide; IVAC alternates with CODOX-M) (Mead, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults &gt;65 years: Cycles 2 and 4 (IVAC): 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (IVAC is combination with cytarabine, mesna, and etoposide; IVAC alternates with CODOX-M) (Mead, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MINE-ESHAP regimen: 1330 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 3 weeks for 6 cycles (MINE is combination with mesna, mitoxantrone, and etoposide; followed by ESHAP) (Rodriguez, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RICE regimen: 5000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (over 24 hours) beginning on day 4 every 2 weeks for 3 cycles (in combination with mesna, carboplatin, etoposide, and rituximab) (Kewalramani, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ewing sarcoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VAC/IE regimen: Adults &le;30 years: IE: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (in combination with mesna and etoposide) alternate with VAC (vincristine, doxorubicin, and cyclophosphamide) every 3 weeks for a total of 17 courses (Grier, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VAIA regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day on days 1, 2, 22, 23, 43, and 44 for 4 courses (in combination with vincristine, doxorubicin, dactinomycin, and mesna) (Paulussen, 2001)",
"     <b>",
"      or",
"     </b>",
"     Adults &le;35 years: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 3 weeks for 14 courses (in combination with vincristine, doxorubicin, dactinomycin, and mesna) (Paulussen, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VIDE regimen: Adults &le;50 years: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 1-3 hours for 3 days every 3 weeks for 6 courses (in combination with vincristine, doxorubicin, etoposide, and mesna) (Juergens, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 1 hour for 5 days every 3 weeks for 12 cycles (in combination with etoposide and mesna) (Miser, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE regimen: Adults &le;22 years: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for up to 12 cycles (in combination with carboplatin and etoposide [and mesna]) (van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteosarcoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifosfamide/cisplatin/doxorubicin/HDMT regimen: Adults &lt;40 years: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days during weeks 4 and 10 (preop) and during weeks 16, 25, and 34 (postop) (in combination with cisplatin, doxorubicin, methotrexate [high-dose], and mesna) (Bacci, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifosfamide/cisplatin/epirubicin regimen: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 3 days (days 2, 3, and 4) every 3 weeks for 3 cycles (preop) and every 4 weeks for 3 cycles (postop) (in combination with cisplatin, epirubicin, and mesna) (Basaran, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE regimen (adults &le;22 years): 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for up to 12 cycles (in combination with carboplatin and etoposide [and mesna]) (van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Soft tissue sarcoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single-agent ifosfamide: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 3 days every 3 weeks for at least 2 cycles or until disease progression (van Oosterom, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE regimen: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every 4 weeks for 4-6 cycles (in combination with carboplatin, etoposide, and regional hyperthermia) (Nickenig, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MAID regimen:  2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 3 days every 3 weeks (in combination with mesna, doxorubicin, and dacarbazine) (Antman, 1993)",
"     <b>",
"      or",
"     </b>",
"     2500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 3 days every 3 weeks (in combination with mesna, doxorubicin, and dacarbazine); reduce ifosfamide to 1500mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day if prior pelvic irradiation (Elias, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifosfamide/epirubicin: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 1 hour for 5 days every 3 weeks for 5 cycles (in combination with mesna and epirubicin) (Frustaci, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AIM regimens: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 4 days every 3 weeks for 4-6 cycles (in combination with mesna and doxorubicin) (Worden, 2005)",
"     <b>",
"      or",
"     </b>",
"     2000-3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 3 hours  for 3 days (in combination with mesna and doxorubicin) (Grobmyer, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F181807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/33/11800?source=see_link\">",
"      see \"Ifosfamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also consult details concerning dosing in combination regimens.",
"     <b>",
"      Note:",
"     </b>",
"     To prevent bladder toxicity, ifosfamide should be given with the urinary protector mesna and hydration of at least 2 L of oral or I.V. fluid per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ewing sarcoma (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VAC/IE regimen: IE: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (in combination with mesna and etoposide) alternate with VAC (vincristine, doxorubicin, and cyclophosphamide) every 3 weeks for a total of 17 courses (Grier, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE-CAV regimen: ICE: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-4 weeks for 2 courses (in combination with carboplatin and etoposide [and mesna]), followed by CAV (cyclophosphamide, doxorubicin, and vincristine) (Milano, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VAIA regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, 22, 23, 43, and 44 for 4 courses (in combination with vincristine, doxorubicin, dactinomycin, and mesna) (Paulussen, 2001)",
"     <b>",
"      or",
"     </b>",
"     2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 3 weeks for 14 courses (in combination with vincristine, doxorubicin, dactinomycin, and mesna) (Paulussen, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VIDE regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 1-3 hours for 3 days every 3 weeks for 6 courses (in combination with vincristine, doxorubicin, etoposide, and mesna) (Juergens, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 1 hour for 5 days every 3 weeks for 12 cycles (in combination with etoposide and mesna) (Miser, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE regimen: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for up to 12 cycles (in combination with carboplatin and etoposide [and mesna]) (van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteosarcoma (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifosfamide/cisplatin/doxorubicin/HDMT regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 5 days during weeks 4 and 10 (preop) and during weeks 16, 25, and 34 (postop) (in combination with cisplatin, doxorubicin, methotrexate [high-dose], and mesna) (Bacci, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifosfamide/cisplatin/epirubicin regimen: Children &ge;15 years: 2000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 4 hours for 3 days (days 2, 3, and 4) every 3 weeks for 3 cycles (preop) and every 4 weeks for 3 cycles (postop) (in combination with cisplatin, epirubicin, and mesna) (Basaran, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IE regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 3 hours for 4 days every 3-4 weeks (in combination with etoposide and mesna) (Gentet, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ICE regimen: Children &ge;1 year: 1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3 weeks for up to 12 cycles (in combination with carboplatin and etoposide [and mesna]) (van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifosfamide/HDMT/etoposide regimen: 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 3 hours for 4 days during weeks 4 and 9 (3 additional postop courses were administered in good responders) (in combination with methotrexate [high-dose], etoposide, and mesna) (Le Deley, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F181786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: Consider dosage reduction in patients with renal impairment; however, no dosage adjustment is provided in the manufacturer&rsquo;s labeling; ifosfamide (and metabolites) are excreted renally and may accumulate in patients with renal dysfunction. Ifosfamide and metabolites are dialyzable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;\">",
"     The following adjustments have also been recommended:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: Children and Adults: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Children and Adults: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis (supplement for dialysis):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children: 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     followed by hemodialysis 6-8 hours later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: No supplemental dose needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 70% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F181787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, ifosfamide is extensively hepatically metabolized to both active and inactive metabolites; use with caution. The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Floyd, 2006: Bilirubin &gt;3 mg/dL: Administer 25% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in manufacturer labeling; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 3 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ifex: 1 g, 3 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 50 mg/mL (20 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. over at least 30 minutes (infusion times may vary by protocol; refer to specific protocol for infusion duration)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F181834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, caspofungin, doripenem, doxorubicin liposome, etoposide phosphate, filgrastim, fludarabine, gallium nitrate, gemcitabine, granisetron, linezolid, melphalan, mesna, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, propofol, sargramostim, sodium bicarbonate, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Epirubicin, mesna.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Mesna with epirubicin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     U.S. labeling: Treatment (third-line) of germ cell testicular cancer (in combination with other chemotherapy drugs and with concurrent mesna)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling (not approved indications in the U.S.): Treatment of soft tissue sarcoma, pancreatic cancer (relapsed or refractory), cervical cancer (advanced or recurrent; as monotherapy or in combination with cisplatin and bleomycin)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4811887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bladder cancer (metastatic), cervical cancer (recurrent or metastatic), head and neck cancers (recurrent or metastatic), ovarian cancer, small cell lung cancer (relapsed), Hodgkin lymphoma (relapsed or refractory), non-Hodgkin lymphomas, thymomas and thymic cancers (advanced), sarcomas (Ewing&rsquo;s sarcoma, osteosarcoma, and soft tissue sarcoma)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ifosfamide may be confused with cyclophosphamide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CNS toxicity or encephalopathy (12% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (83% to 90%; 100% with combination therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis (31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (47% to 58%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (50% to &le;100%; grade 4: &le;50%; nadir: 8-14 days), anemia (38%), thrombocytopenia (20%; grades 3/4: &le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (6% to 92%; reduced with mesna; grade 2 [gross hematuria]: 8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (2% to 3%), liver dysfunction (2% to 3%), transaminases increased (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal impairment (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (8% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome, acute tubular necrosis, agranulocytosis, alkaline phosphatase increased, allergic reaction, alveolitis (allergic), amenorrhea, aminoaciduria, amnesia, anaphylactic reaction, angina, angioedema, anuria, arrhythmia, arthralgia, asterixis, atrial ectopy, atrial fibrillation/flutter, azoospermia, bladder irritation, bleeding, blurred vision, bone marrow failure, bradycardia, bradyphrenia, bronchospasm, bundle branch block, BUN increased, capillary leak syndrome, cardiac arrest, cardiogenic shock, cardiomyopathy, cardiotoxicity, catatonia, cecitis, chest pain, cholestasis, coagulopathy, colitis, conjunctivitis, creatinine clearance decreased/increased, creatinine increased, cylindruria, cytolytic hepatitis, delirium, delusion, dermatitis, diarrhea, DIC, DVT, dysesthesia, dyspnea, dysuria, echolalia, edema, ejection fraction decreased, enterocolitis, enuresis, enzymuria, erythema, extrapyramidal disorder, facial swelling, Fanconi syndrome, fatigue, gait disturbance, GGT increased, GI hemorrhage, glycosuria, gonadotropin increased, granulocytopenia, growth retardation (children), hemolytic anemia, hemolytic uremic syndrome, hemorrhagic cystitis, hepatic failure, hepatic sinusoidal obstruction syndrome (SOS; formerly veno-occlusive disease [VOD]), hepatitis fulminant, hepatitis (viral), hepatorenal syndrome, herpes zoster, hyperglycemia, hyper-/hypotension, hypersensitivity reactions, hypocalcemia, hypokalemia, hyponatremia, hypophosphatemia, hypoxia, ileus, immunosuppression, infertility, infusion site reactions (erythema, inflammation, pain, pruritus, swelling, tenderness), interstitial lung disease, jaundice, LDH increased, leukoencephalopathy, lymphopenia, malaise, mania, mental status change, methemoglobinemia, MI, mucosal inflammation/ulceration, multiorgan failure, mutism, myocardial hemorrhage, myocarditis, nephrogenic diabetes insipidus, neuralgia, neutropenia, oligospermia, oliguria, osteomalacia (adults), ovarian failure, ovulation disorder, palmar-plantar erythrodysesthesia syndrome, pancreatitis, pancytopenia, panic attack, paranoia, paresthesia, pericardial effusion, pericarditis, peripheral neuropathy, petechiae, phosphaturia, pleural effusion,",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia, pneumonia, pneumonitis, pollakiuria, polydipsia, polyneuropathy, polyuria, portal vein thrombosis, premature atrial contractions, premature menopause, progressive multifocal leukoencephalopathy, proteinuria, pruritus, pulmonary edema, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, QRS complex abnormal, radiation recall dermatitis, rash (including macular and papular), renal failure, renal parenchymal damage, renal tubular acidosis, respiratory failure, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, rickets, salivation, secondary malignancy, seizure, sepsis, septic shock, SIADH, skin necrosis, spermatogenesis impaired, status epilepticus, sterility, Stevens-Johnson syndrome, stomatitis, ST segment abnormal, supraventricular extrasystoles, tachycardia, tinnitus, toxic epidermal necrolysis, tubulointerstitial nephritis, tumor lysis syndrome, T-wave inversion, uremia, urticaria, vasculitis, ventricular extrasystoles/fibrillation/tachycardia, ventricular failure, vertigo, visual impairment, wound healing impairment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ifosfamide or any component of the formulation; urinary outflow obstruction",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe myelosuppression; severe renal or hepatic impairment; active infection (bacterial, fungal, viral); severe immunosuppression; urinary tract disease (eg, cystitis); advanced cerebral arteriosclerosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Anaphylactic/anaphylactoid reactions have been associated with ifosfamide. Cross sensitivity with similar agents may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe bone marrow suppression may occur (dose-limiting toxicity); monitor blood counts before and after each cycle.",
"     </b>",
"     Leukopenia, neutropenia, thrombocytopenia, and anemia are associated with ifosfamide. Myelosuppression is dose dependent, increased with single high  doses (compared to fractionated doses) and increased with decreased renal function. Severe myelosuppression may occur when administered in combination with other chemotherapy agents or radiation therapy. Use with caution in patients with compromised bone marrow reserve. Unless clinically necessary, avoid administering to patients with WBC &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Antimicrobial prophylaxis may be necessary in some neutropenic patients; Administer antibiotics and/or antifungal agents for neutropenic fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiotoxicity: Arrhythmias, ST-segment or T-wave changes, cardiomyopathy, pericardial effusion, pericarditis, and epicardial fibrosis have been observed. The risk for cardiotoxicity is dose-dependent; concomitant cardiotoxic agents (eg, anthracyclines), irradiation of the cardiac region, and renal impairment may also increase the risk. Use with caution in patients with cardiac risk factors or pre-existing cardiac disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause CNS toxicity which may be severe, resulting in encephalopathy and death; monitor for CNS toxicity; discontinue for encephalopathy.",
"     </b>",
"     Symptoms of CNS toxicity (somnolence, confusion, dizziness, disorientation, hallucinations, cranial nerve dysfunction, psychotic behavior, extrapyramidal symptoms, seizures, coma, blurred vision, and/or incontinence) have been observed within a few hours to a few days after initial dose, and generally resolve within 2-3 days of  treatment discontinuation (although may persist longer); maintain supportive care until complete resolution. Risk factors may include hypoalbuminemia, renal dysfunction, and prior history of ifosfamide-induced encephalopathy. Concomitant centrally-acting medications may result in additive CNS effects. Peripheral neuropathy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhagic cystitis:",
"     <b>",
"      [U.S. Boxed Warning]: Hemorrhagic cystitis may occur; concomitant mesna reduces the risk of hemorrhagic cystitis.",
"     </b>",
"     Hydration (at least 2 L/day), dose fractionation, and/or mesna administration will reduce the incidence of hematuria and protect against hemorrhagic cystitis. Obtain urinalysis prior to each dose; if microscopic hematuria is detected, withhold until complete resolution. Exclude or correct urinary tract obstructions prior to treatment. Use with caution (if at all) in patients with active urinary tract infection. Hemorrhagic cystitis is dose-dependent and is increased with high single doses (compared with fractionated doses); past or concomitant bladder radiation or busulfan treatment may increase the risk for hemorrhagic cystitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic sinusoidal obstruction syndrome (SOS), formerly called veno-occlusive disease (VOD), has been reported with ifosfamide-containing regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression:  May cause significant suppression of the immune responses; may lead to serious infection, sepsis or septic shock. Reported infections have included bacterial, viral, fungal, and parasitic; latent infections may be reactivated. Use with caution with other immunosuppressants or in patients with infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Interstitial pneumonitis, pulmonary fibrosis, and pulmonary toxicity leading to respiratory failure have been reported. Monitor for signs and symptoms of pulmonary toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe nephrotoxicity, resulting in renal failure.",
"     </b>",
"     Acute and chronic renal failure, as well as renal parenchymal and tubular necrosis (including acute), have been reported; tubular damage may be delayed and may persist. Renal manifestations include decreased glomerular rate, increased creatinine, proteinuria, enzymuria, cylindruria, aminoaciduria, phosphaturia, and glycosuria. Syndrome of inappropriate antidiuretic hormone (SIADH), renal rickets, and Fanconi syndrome have been reported. Evaluate renal function prior to and during treatment; monitor urine for erythrocytes and signs of urotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy: Secondary malignancies may occur; the risk for myelodysplastic syndrome (which may progress to acute leukemia) is increased with treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound healing: May interfere with wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy: Use with caution in patients with prior radiation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (major), CYP2B6 (minor), CYP2C19 (major), CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: May enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inducers (Strong): May increase the metabolism of CYP2A6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inhibitors (Moderate): May decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Inhibitors (Strong): May decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ifosfamide may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F181776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease ifosfamide levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4811888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxic and teratogenic effects have been observed in animal reproduction studies. Fetal growth retardation and neonatal anemia have been reported with exposure to ifosfamide-containing regimens during human pregnancy. Male and female fertility may be affected (dose and duration dependent). Ifosfamide interferes with oogenesis and spermatogenesis; amenorrhea, azoospermia, and sterility have been reported and may be irreversible. Avoid pregnancy during treatment; male patients should not father a child for at least 6 months after completion of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14584080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Breast-feeding should be avoided during ifosfamide treatment. According to the manufacturer, the decision to discontinue ifosfamide or discontinue breast-feeding should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ifosfamide Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/20 mL (20 mL): $50.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 g/60 mL (60 mL): $187.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ifex Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $79.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 g (1): $125.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ifosfamide Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $44.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 g (1): $129.05",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (prior to each dose), urine output, urinalysis (prior to each dose), liver function, and renal function tests; signs and symptoms of neurotoxicity, pulmonary toxicity, and/or hemorrhagic cystitis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F181766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cuantil (AR, PY);",
"     </li>",
"     <li>",
"      Farmamide (DE);",
"     </li>",
"     <li>",
"      Holoxan (AE, AT, AU, BD, BE, BG, BH, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GR, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LU, LY, MT, MY, NL, NO, NZ, OM, PH, PK, PL, PT, QA, RU, SA, SE, SG, SK, SY, TH, TR, TW, UY, YE);",
"     </li>",
"     <li>",
"      Holoxane (BR);",
"     </li>",
"     <li>",
"      Ifadex (MX);",
"     </li>",
"     <li>",
"      Ifolem (MX, TH);",
"     </li>",
"     <li>",
"      Ifomida (MX);",
"     </li>",
"     <li>",
"      Ifomide (JP);",
"     </li>",
"     <li>",
"      Ifos (PE);",
"     </li>",
"     <li>",
"      Ipamide (IN);",
"     </li>",
"     <li>",
"      Iphox (PH);",
"     </li>",
"     <li>",
"      Mitoxana (GB);",
"     </li>",
"     <li>",
"      Tolcamin (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes cross-linking of strands of DNA by binding with nucleic acids and other intracellular structures; inhibits protein synthesis and DNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacokinetics are dose dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Approximates total body water; penetrates CNS, but not in therapeutic levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolites isofosforamide mustard, 4-hydroxy-ifosfamide, acrolein, and inactive dichloroethylated and carboxy metabolites; acrolein is the agent implicated in development of hemorrhagic cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (increased in the elderly):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High dose (3800-5000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): ~15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lower dose (1600-2400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High dose (5000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Urine (70% to 86%; 61% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lower dose (1600-2400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Urine (12% to 18% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antman K, Crowley J, Balcerzak SP, et al, &ldquo;An Intergroup Phase III Randomized Study of Doxorubicin and Dacarbazine With or Without Ifosfamide and Mesna in Advanced Soft Tissue and Bone Sarcomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(7):1276-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/8315425/pubmed\" id=\"8315425\" target=\"_blank\">",
"        8315425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman K, Crowley J, Balcerzak SP, et al, &ldquo;A Southwest Oncology Group and Cancer and Leukemia Group B phase II Study of Doxorubicin, Dacarbazine, Ifosfamide, and Mesna in Adults With Advanced Osteosarcoma, Ewing's Sarcoma, and Rhabdomyosarcoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1998, 82(7):1288-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/9529020/pubmed\" id=\"9529020\" target=\"_blank\">",
"        9529020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100, 172.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bacci G, Briccoli A, Rocca M, et al, &ldquo;Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities With Metastases at Presentation: Recent Experience at the Rizzoli Institute in 57 Patients Treated With Cisplatin, Doxorubicin, and a High Dose of Methotrexate and Ifosfamide,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2003, 14(7):1126-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/12853357/pubmed\" id=\"12853357\" target=\"_blank\">",
"        12853357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Basaran M, Bavbek ES, Saglam S, et al, &ldquo;A Phase II Study of Cisplatin, Ifosfamide and Epirubicin Combination Chemotherapy in Adults With Nonmetastatic and Extremity Osteosarcomas,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 2007, 72(3-4):255-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/18185020/pubmed\" id=\"18185020\" target=\"_blank\">",
"        18185020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleman RE, Harper PG, Gallagher C, et al, &ldquo;A Phase II Study of Ifosfamide in Advanced and Relapsed Carcinoma of the Cervix,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1986, 18(3):280-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/3802384/pubmed\" id=\"3802384\" target=\"_blank\">",
"        3802384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      David KA and Picus J, &ldquo;Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 2005, 28(3):277-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/15923801/pubmed\" id=\"15923801\" target=\"_blank\">",
"        15923801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2011, 57(2):191-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/21465637/pubmed\" id=\"21465637\" target=\"_blank\">",
"        21465637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elias A, Ryan L, Sulkes A, et al, &ldquo;Response to Mesna, Doxorubicin, Ifosfamide, and Dacarbazine in 108 Patients With Metastatic or Unresectable Sarcoma and No Prior Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(9):1208-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/2504890/pubmed\" id=\"2504890\" target=\"_blank\">",
"        2504890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez de Larrea C, Martinez C, Gaya A, et al, &ldquo;Salvage Chemotherapy With Alternating MINE-ESHAP Regimen in Relapsed or Refractory Hodgkin&rsquo;s Lymphoma Followed By Autologous Stem-Cell Transplantation,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(6):1211-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/19889622/pubmed\" id=\"19889622\" target=\"_blank\">",
"        19889622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrari S, Ruggieri P, Cefalo G, et al, &ldquo;Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(17):2112-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/22564997/pubmed\" id=\"22564997\" target=\"_blank\">",
"        22564997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frustaci S, Gherlinzoni F, De Paoli A, et al, &ldquo;Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(5):1238-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/11230464/pubmed\" id=\"11230464\" target=\"_blank\">",
"        11230464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gentet JC, Brunat-Mentigny M, Demaille MC, et al, &ldquo;Ifosfamide and Etoposide in Childhood Osteosarcoma. A Phase II Study of the French Society of Paediatric Oncology,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1997, 33(2):232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/9135494/pubmed\" id=\"9135494\" target=\"_blank\">",
"        9135494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, \"Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grobmyer ST, Maki RG, Demetri GD, et al, &ldquo;Neo-Adjuvant Chemotherapy for Primary High-Grade Extremity Soft Tissue Sarcoma,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(11):1667-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/15520069/pubmed\" id=\"15520069\" target=\"_blank\">",
"        15520069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juergens C, Weston C, Lewis I, et al, &ldquo;Safety Assessment of Intensive Induction With Vincristine, Ifosfamide, Doxorubicin, and Etoposide (VIDE) in the Treatment of Ewing Tumors in the EURO-E.W.I.N.G. 99 Clinical Trial,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 47(1):22-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/16572419/pubmed\" id=\"16572419\" target=\"_blank\">",
"        16572419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerbusch T, de Kraker J, Keizer HJ, et al, \"Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2001, 40(1):41-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/11236809/pubmed\" id=\"11236809\" target=\"_blank\">",
"        11236809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kewalramani T, Zelenetz AD, Nimer SD, et al, &ldquo;Rituximab and ICE as Second-Line Therapy before Autologous Stem Cell Transplantation for Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(10):3684-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/14739217 /pubmed\" id=\"14739217 \" target=\"_blank\">",
"        14739217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kilickap S, Cakar M, Onal IK, et al, &ldquo;Nonconvulsive Status Epilepticus Due to Ifosfamide,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(2):332-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/16449538/pubmed\" id=\"16449538\" target=\"_blank\">",
"        16449538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondagunta GV, Bacik J, Donadio A, et al, &ldquo;Combination of Paclitaxel, Ifosfamide, and Cisplatin is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(27):6549-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/16170162/pubmed\" id=\"16170162\" target=\"_blank\">",
"        16170162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondagunta GV, Bacik J, Sheinfeld J, et al, &ldquo;Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(1):85-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/17194908/pubmed\" id=\"17194908\" target=\"_blank\">",
"        17194908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le Deley MC, Guinebreti&egrave;re JM, Gentet JC, et al, &ldquo;SFOP OS94: a Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2007, 43(4):752-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/17267204/pubmed\" id=\"17267204\" target=\"_blank\">",
"        17267204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loehrer PJ Sr, Gonin R, Nichols CR, et al, &ldquo;Vinblastine Plus Ifosfamide Plus Cisplatin as Initial Salvage Therapy in Recurrent Germ Cell Tumor,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(7):2500-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/9667270/pubmed\" id=\"9667270\" target=\"_blank\">",
"        9667270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loehrer PJ Sr, Jiroutek M, Aisner S, et al, &ldquo;Combined Etoposide, Ifosfamide, and Cisplatin in the Treatment of Patients With Advanced Thymoma and Thymic Carcinoma: An Intergroup Trial,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 91(11):2010-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/11391579/pubmed\" id=\"11391579\" target=\"_blank\">",
"        11391579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lotz JP, Bouleuc C, Andre T, et al, &ldquo;Tandem High-Dose Chemotherapy With Ifosfamide, Carboplatin, and Teniposide With Autologous Bone Marrow Transplantation for the Treatment of Poor Prognosis Common Epithelial Ovarian Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1996, 77(12):2550-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/8640705/pubmed\" id=\"8640705\" target=\"_blank\">",
"        8640705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead GM, Barrans SL, Qian W, et al, \"A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial),\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(6):2248-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/18612102/pubmed\" id=\"18612102\" target=\"_blank\">",
"        18612102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milano GM, Cozza R, Ilari I, et al, &ldquo;High Histologic and Overall Response to Dose Intensification of Ifosfamide, Carboplatin, and Etoposide With Cyclophosphamide, Doxorubicin, and Vincristine in Patients With High-Risk Ewing Sarcoma Family Tumors: The Bambino Ges&ugrave; Children's Hospital Experience,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(8):1838-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/16532434/pubmed\" id=\"16532434\" target=\"_blank\">",
"        16532434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miser JS, Kinsella TJ, Triche TJ, et al, &ldquo;Ifosfamide With Mesna Uroprotection and Etoposide: An Effective Regimen in the Treatment of Recurrent Sarcomas and Other Tumors of Children and Young Adults,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1987, 5(8):1191-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/3114435/pubmed\" id=\"3114435\" target=\"_blank\">",
"        3114435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moskowitz CH, Nimer SD, Zelenetz AD, et al, \"A 2-Step Comprehensive High-Dose Chemoradiotherapy Second-Line Program for Relapsed and Refractory Hodgkin Disease: Analysis by Intent to Treat and Development of a Prognostic Model,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 97(3):616-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/11157476/pubmed\" id=\"11157476\" target=\"_blank\">",
"        11157476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 1.2013. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichols CR, Catalano PJ, Crawford ED, et al, &ldquo;Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(4):1287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/9552027 /pubmed\" id=\"9552027 \" target=\"_blank\">",
"        9552027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nickenig C, Buecklein L, Lindner LH, et al, &ldquo;Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination With Regional Hyperthermia (RHT) in Chemotherapy-Pretreated Nonresponders With Locally Advanced High-Risk Soft Tissue Sarcoma (HR-STS),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s): 10581 [abstract 10581 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paulussen M, Ahrens S, Dunst J, et al, &ldquo;Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing's Sarcoma Study CESS 86,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(6):1818-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/11251014/pubmed\" id=\"11251014\" target=\"_blank\">",
"        11251014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paulussen  M, Craft AW, Lewis I, et al, &ldquo;Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment--Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(27):4385-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/18802150/pubmed\" id=\"18802150\" target=\"_blank\">",
"        18802150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelgrims J, DeVos F, Van den Brande J, et al, &ldquo;Methylene Blue in the Treatment and Prevention of Ifosfamide-Induced Encephalopathy: Report of 12 Cases and a Review of the Literature,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2000, 82(2) 291-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/10646879/pubmed\" id=\"10646879\" target=\"_blank\">",
"        10646879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips JK, Spearing RL, Davies JM, et al, \"VIM-D Salvage Chemotherapy in Hodgkin's Disease,\"",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1990, 27(2):161-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/2249334 /pubmed\" id=\"2249334 \" target=\"_blank\">",
"        2249334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez MA, Cabanillas FC, Velasquez W, et al, &ldquo;Results of a Salvage Treatment Program for Relapsing Lymphoma: MINE Consolidated With ESHAP,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(7):1734-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/7602363 /pubmed\" id=\"7602363 \" target=\"_blank\">",
"        7602363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santoro A, Magagnoli M, Spina M, et al, \"Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin's Lymphoma,\"",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2007, 92(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/17229633/pubmed\" id=\"17229633\" target=\"_blank\">",
"        17229633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shin DM, Khuri FR, Glisson BS, et al, &ldquo;Phase II Study of Paclitaxel, Ifosfamide, and Carboplatin in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 91(7):1316-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/11283932/pubmed\" id=\"11283932\" target=\"_blank\">",
"        11283932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sutton GP, Blessing JA, DiSaia PJ, et al, &ldquo;Phase II Study of Ifosfamide and Mesna in Nonsquamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 1993, 49(1):48-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/8482560/pubmed\" id=\"8482560\" target=\"_blank\">",
"        8482560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turner AR, Duong CD, and Good DJ, &ldquo;Methylene Blue for the Treatment and Prophylaxis of Ifosfamide-Induced Encephalopathy,&rdquo;",
"      <i>",
"       Clin Oncol",
"      </i>",
"      , 2003, 15(7):435-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/14570094/pubmed\" id=\"14570094\" target=\"_blank\">",
"        14570094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Oosterom AT, Mouridsen HT, Nielsen OS, et al, &ldquo;Results of Randomised Studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) With Two Different Ifosfamide Regimens in First- and Second-Line Chemotherapy in Advanced Soft Tissue Sarcoma Patients,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2002, 38(18):2397-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/12460784/pubmed\" id=\"12460784\" target=\"_blank\">",
"        12460784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Winkle P, Angiolillo A, Krailo M, et al, &ldquo;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children&rsquo;s Cancer Group (CCG) Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(4):338-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/15503297/pubmed\" id=\"15503297\" target=\"_blank\">",
"        15503297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Witte RS, Elson P, Bono B, et al, &ldquo;Eastern Cooperative Oncology Group Phase II Trial of Ifosfamide in the Treatment of Previously Treated Advanced Urothelial Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(2):589-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/9053481/pubmed\" id=\"9053481\" target=\"_blank\">",
"        9053481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worden FP, Taylor JM, Biermann JS, et al, &ldquo;Randomized Phase II Evaluation of 6 g/m",
"      <sup>",
"       2",
"      </sup>",
"      of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m",
"      <sup>",
"       2",
"      </sup>",
"      of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(1):105-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/25/38297/abstract-text/15625365/pubmed\" id=\"15625365\" target=\"_blank\">",
"        15625365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8552 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-6ADEC3818C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38297=[""].join("\n");
var outline_f37_25_38297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708917\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181779\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181780\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181828\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181784\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181807\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181785\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181786\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181787\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181758\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181743\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181761\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181834\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181759\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4811887\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136825\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181826\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181764\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181747\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181823\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181752\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181776\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181754\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4811888\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181794\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14584080\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323192\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181756\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181766\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181746\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181763\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8552\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8552|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/46/19173?source=related_link\">",
"      Ifosfamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/33/11800?source=related_link\">",
"      Ifosfamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38298="Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus";
var content_f37_25_38298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38298/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38298/contributors\">",
"     Kathleen Dungan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38298/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/25/38298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/25/38298/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/25/38298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in options for the treatment of diabetes, optimal glycemic control is often not achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/1\">",
"     1",
"    </a>",
"    ]. Hypoglycemia and weight gain associated with many anti-diabetic medications may interfere with the implementation and long-term application of \"intensive\" therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Treatment has centered on increasing insulin availability, either through direct insulin administration or through oral agents that promote insulin secretion, on improving sensitivity to insulin, or on delaying the delivery and absorption of carbohydrate from the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Glucose homeostasis is dependent on a complex interplay of multiple hormones: insulin and amylin, produced by pancreatic beta cells; glucagon, produced by pancreatic alpha cells; and gastrointestinal peptides, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP; gastric inhibitory polypeptide) (",
"    <a class=\"graphic graphic_figure graphicRef59551 \" href=\"mobipreview.htm?42/1/43025\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/5\">",
"     5",
"    </a>",
"    ]. Abnormal regulation of these substances may contribute to the clinical presentation of diabetes.",
"   </p>",
"   <p>",
"    GLP-1-based therapies affect glucose control through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric emptying, regulation of postprandial glucagon, and reduction of food intake (",
"    <a class=\"graphic graphic_table graphicRef51832 \" href=\"mobipreview.htm?11/44/11979\">",
"     table 1",
"    </a>",
"    ). These agents do not cause hypoglycemia, in the absence of therapies that otherwise cause hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the mechanism of action and therapeutic utility of GLP-1-based therapies for the treatment of type 2 diabetes mellitus. GLP-1-based therapies should not be used in patients with type 1 diabetes. An overview of pharmacologic therapy for type 1 and type 2 diabetes is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLUCAGON-LIKE PEPTIDE-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of GLP-1 in glucose homeostasis is illustrative of the incretin effect, in which oral glucose has a greater stimulatory effect on insulin secretion than intravenous glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/7\">",
"     7",
"    </a>",
"    ]. This effect is mediated by several gastrointestinal peptides, particularly GLP-1.",
"   </p>",
"   <p>",
"    GLP-1 is produced from the proglucagon gene in L-cells of the small intestine and is secreted in response to nutrients (",
"    <a class=\"graphic graphic_figure graphicRef59551 \" href=\"mobipreview.htm?42/1/43025\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/8\">",
"     8",
"    </a>",
"    ]. GLP-1 levels are decreased in type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef59286 graphicRef72099 graphicRef81642 \" href=\"mobipreview.htm?13/48/14082\">",
"     figure 2A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/9\">",
"     9",
"    </a>",
"    ], and GLP-1 regulation may be abnormal in type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/10\">",
"     10",
"    </a>",
"    ]. The role of GLP-1 in the treatment of type 1 diabetes is under investigation, but is not well-defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/11\">",
"     11",
"    </a>",
"    ]. GLP-1-based therapies should not be used in patients with type 1 diabetes. Therefore, this discussion will be limited to its use in type 2 diabetes.",
"   </p>",
"   <p>",
"    GLP-1 exerts its main effect by stimulating glucose-dependent insulin release from the pancreatic islets. It restores both first phase and second phase insulin response to glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/12\">",
"     12",
"    </a>",
"    ]. It has also been shown to slow gastric emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/13\">",
"     13",
"    </a>",
"    ], inhibit inappropriate post-meal glucagon release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and reduce food intake (",
"    <a class=\"graphic graphic_table graphicRef51832 \" href=\"mobipreview.htm?11/44/11979\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Owing in part to the effects of GLP-1 on slowed gastric emptying and its well recognized side effects of nausea and vomiting, therapy with GLP-1 and its analogs is associated with weight loss. The role of GLP-1 as a weight loss agent in patients without diabetes is under investigation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link&amp;anchor=H28#H28\">",
"     \"Drug therapy of obesity\", section on 'Diabetes drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animal models, GLP-1 stimulates beta-cell proliferation and differentiation, preventing diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, GLP-1 may hold promise for halting the progression of beta cell failure that often occurs in type 2 diabetes.",
"   </p>",
"   <p>",
"    GLP-1 exhibits a short half-life of one to two minutes due to N-terminal degradation by the enzyme dipeptidyl peptidase 4 (DPP-4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/19\">",
"     19",
"    </a>",
"    ]. This necessitates continuous infusion of GLP-1 to achieve steady state levels in pharmacologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/20\">",
"     20",
"    </a>",
"    ]. Research has focused on GLP-1-like analogs that are resistant to DPP-4 degradation and on agents that increase GLP-1 via inhibition of DPP-4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLP-1 ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no long-term studies of GLP-1 analogs to assess durability of weight loss, clinically important health outcomes (cardiovascular events, mortality), or safety. Many questions remain unanswered regarding clinical use in type 2 diabetes, including long-term benefits and risks and their role in combination with other diabetes medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, they are not considered as initial therapy for the majority of patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GLP-1 analogs are effective in improving glycemic control, as illustrated by the findings of a meta-analysis of 17 randomized trials comparing GLP-1 analogs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    , albiglutide, taspoglutide, lixisenatide) with placebo or an active comparator (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    , DPP-4 inhibitor, thiazolidinedione, sulfonylurea) in patients with type 2 diabetes and suboptimal control on one or two oral agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sulfonylurea) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/23\">",
"     23",
"    </a>",
"    ]. The duration of the individual trials ranged from 8 to 30 weeks. In comparison to placebo, all GLP-1 analogs reduced A1C by approximately 1 percentage point (treatment difference 0.47 to 1.56 percent).",
"   </p>",
"   <p>",
"    In comparison to thiazolidinediones, DPP-4 inhibitors, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    was superior in reducing A1C. Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    once weekly (2 mg) reduced A1C more than thiazolidinediones, DPP-4 inhibitors, exenatide (10 mcg twice daily), and insulin glargine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/23\">",
"     23",
"    </a>",
"    ]. The comparisons between GLP-1 analogs and active treatment (eg, insulin glargine) should be interpreted with caution. In some of the trials, the active comparators, especially insulin, were often not adjusted as aggressively as they could or should have been, based on labeling and usual clinical practice. In addition, although the reported reductions in A1C for GLP-1 analogs versus insulin glargine were statistically significant, the difference was small (0.2 percentage points) and of uncertain clinical significance.",
"   </p>",
"   <p>",
"    Hypoglycemia occurred more often in participants taking concomitant sulfonylureas. Patients randomly assigned to treatment with GLP-1 analogs compared with placebo or active comparator experienced more nausea (8 to 40 percent more), diarrhea (3 to 118 percent more), and weight loss (-1.3 to -5.1 kg).",
"   </p>",
"   <p>",
"    The reduction in body weight with GLP-1 analog treatment was confirmed in another meta-analysis of 21 industry-sponsored trials comparing GLP-1 analogs with placebo, no intervention, or other diabetes medications in overweight patients with or without diabetes (weighted mean difference -2.9 kg, 95% CI -3.6 to -2.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/24\">",
"     24",
"    </a>",
"    ]. Weight reduction occurred in patients with (18 trials) and without (three trials) diabetes (mean difference -2.8 and -3.2 kg, respectively). The majority of the trials in the meta-analysis were designed primarily to assess the effect of GLP-1 analogs on glycemic control. Body weight was a secondary endpoint. In addition, there was significant heterogeneity in the results due to differences in trial design. Some of the comparators (sulfonylureas, insulin, thiazolidinediones) cause weight gain, while others (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ) cause weight loss, and still others (placebo, no intervention, DPP-4 inhibitors) are weight neutral. Subgroup analyses showed a significant but smaller mean change in body weight in the trials in which the control group received placebo (-1.9 kg), and a larger difference when the comparator was insulin (-4.8 kg). The duration of the individual trials in the meta-analyses ranged from 20 to 52 weeks. Some of the individual trials are reviewed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Exenatide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exendin-4 is a naturally occurring component of the Gila monster (Heloderma suspectum) saliva, and shares 53 percent sequence identity with GLP-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/25\">",
"     25",
"    </a>",
"    ]. It is resistant to DPP-4 degradation and therefore exhibits a prolonged half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    (half-life 2.4 hours) is synthetic exendin-4. It is approved in the United States for the treatment of type 2 diabetes as monotherapy or in combination with oral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    has been shown to bind to the GLP-1 receptor of rat islets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/28\">",
"     28",
"    </a>",
"    ]. Exenatide, like GLP-1, has been shown to promote beta cell regeneration and differentiation in prediabetic and diabetic rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    exhibits dose-dependent and glucose-dependent augmentation of insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/6\">",
"     6",
"    </a>",
"    ]. Its insulinotropic effects are suppressed as the plasma glucose approaches 4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (72",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/6\">",
"     6",
"    </a>",
"    ]. Like GLP-1, exenatide slows gastric emptying, suppresses inappropriately elevated glucagon levels, and leads to weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/28,32\">",
"     28,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29018503\">",
"    <span class=\"h4\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several studies examining the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    , either 5 or 10 mcg twice daily, versus placebo on glycemic control in patients suboptimally controlled on maximally effective or tolerated doses of sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , combination of sulfonylurea and metformin, or thiazolidinedione therapy (alone or with metformin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. A meta-analysis of these studies reported a greater decline from baseline A1C values in the exenatide group compared with placebo (weighted mean difference in change in A1C -1.01 percent, 95% CI -1.18 to -0.84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients receiving exenatide were more likely to achieve glycemic goals (A1C &le;7 percent) compared with patients receiving placebo (45 versus 10 percent, respectively).",
"   </p>",
"   <p>",
"    Although all of these studies were less than 30 weeks in duration, open-label extension studies have demonstrated sustained lowering of A1C and continuous weight loss averaging about 5.4 kg (12 pounds) at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Weight loss was associated with improvements in blood pressure and lipids. Of note, the open-label extension studies suffer from a &ldquo;survivor effect,&rdquo; such that only those subjects who remain on the drug are usually included. Thus, these long-term results tend to provide an exaggerated benefit compared with average use.",
"   </p>",
"   <p>",
"    Randomized open-label trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or biphasic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    , combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and a sulfonylurea in patients with poorly controlled type 2 diabetes, demonstrated similar A1C reductions of -0.89 to -1.1 percent in the exenatide and insulin groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In the glargine comparison study, insulin was titrated based upon achieving a target fasting glucose level &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The target level was reached in only 21.6 percent of the subjects randomly assigned to glargine, and the average dose used (25 units) was substantially lower than in most studies. The relatively unaggressive insulin therapy may have balanced overall glycemic control in favor of exenatide. The exenatide groups exhibited weight loss as opposed to weight gain and improved postprandial glucose control compared with either insulin group, and less nocturnal hypoglycemia compared with insulin glargine. Exenatide caused nausea in 33 to 57 percent of patients, resulting in a greater withdrawal rate (approximately 20 percent versus 10 percent for exenatide and insulin, respectively) due to adverse symptoms in both studies.",
"   </p>",
"   <p>",
"    In a randomized open-label trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    in 1029 patients with type 2 diabetes taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (mean baseline A1C 7.5 percent), treatment failure (defined as A1C &gt;9 percent after the first three months of treatment, or &gt;7 percent at two consecutive visits after the first six months) occurred less often in the exenatide group (41 versus 54 percent, HR 0.5, 95% CI 0.62-0.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/41\">",
"     41",
"    </a>",
"    ]. The median time to treatment failure was 180 and 142 weeks for exenatide and glimepiride, respectively. In both groups, A1C initially declined over three months, remained stable for approximately three months, and then slowly increased throughout the remainder of the study (up to 234 weeks). At three years, mean A1C values in the 397 patients who were not discontinued from the study due to treatment failure, or who did not drop out voluntarily, were similar (approximately 7.3 and 7.1 percent, in the glimepiride and exenatide groups, respectively). Of note, the average dose of glimepiride used in the study (2mg daily) was lower than the usual dose (3 to 4 mg) in most studies.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    has also been studied in patients inadequately controlled with diet and exercise alone. In a randomized trial of exenatide versus placebo in 232 drug-naive patients, there were significantly greater improvements in A1C (0.9 versus 0.2 percentage points), weight, and blood pressure in the exenatide group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    and insulin has been evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In a placebo-controlled trial, exenatide added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    reduced A1C by approximately 0.7 percentage points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/43\">",
"     43",
"    </a>",
"    ]. Another randomized trial examined replacement of insulin with exenatide in patients with type 2 diabetes; glycemic control deteriorated in 38 percent (11 of 29 patients) when exenatide was substituted, compared with 19 percent (3 of 16 patients) who continued insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients who lost glycemic control were more likely to have a longer duration of disease, lower C-peptide concentrations (suggesting less endogenous beta cell function), and larger insulin requirements at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29018510\">",
"    <span class=\"h4\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    ; it is dose dependent and progressive without apparent plateau at 30 weeks. A meta-analysis of studies comparing exenatide with placebo injection in patients suboptimally treated on oral hypoglycemic agents reported a significant decrease in weight with exenatide (weighted mean difference in change from baseline -1.44 kg, 95% CI -2.13 to -0.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/36\">",
"     36",
"    </a>",
"    ]. Weight loss is more pronounced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    alone as background therapy than with sulfonylureas or thiazolidinediones (",
"    <a class=\"graphic graphic_figure graphicRef78588 \" href=\"mobipreview.htm?7/7/7280\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Weight loss was not solely due to co-incidence of nausea, although treated patients with nausea lose substantially more weight than patients without nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    are predominantly gastrointestinal. Mild to moderate hypoglycemic events occur only when exenatide is given in conjunction with sulfonylureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]; titrating the dose of sulfonylurea down to the smallest tablet size reduces hypoglycemia without substantially sacrificing efficacy. Exenatide does not alter the counter-regulatory hormone response to insulin-induced hypoglycemia in healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal &mdash; Nausea is a common adverse effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      , but is generally mild to moderate in intensity and wanes with duration of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. Nausea can be reduced with dose titration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There have been 36 postmarketing reports of acute pancreatitis in patients taking exenatide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. In some cases, necrotizing or hemorrhagic pancreatitis was reported, and fatalities occurred [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/49\">",
"       49",
"      </a>",
"      ]. Furthermore, in a population-based case-control study using a large insurance database, treatment with GLP-1-based therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      and exenatide) was associated with an increased risk of hospitalization for acute pancreatitis (adjusted OR 2.07, 95% CI 1.36-3.13) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/51\">",
"       51",
"      </a>",
"      ]. In contrast, retrospective cohort studies have not identified an increased risk, but these studies identified fewer cases overall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Adverse effects'",
"      </a>",
"      below.) There are insufficient data to determine the overall frequency of pancreatitis in exenatide users. The overall reported rate for pancreatitis in exenatide users ranges from 0.33 to 5.7 cases per 1000 patient years and for the more severe necrotizing or hemorrhagic forms, less than 1 in 10,000, which is similar to the background rate in patients with diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/52,54-56\">",
"       52,54-56",
"      </a>",
"      ]. Pancreatitis should be considered in patients with persistent severe abdominal pain (with or without nausea), and exenatide should be discontinued in such patients. If pancreatitis is confirmed, it should not be restarted.",
"     </li>",
"     <li>",
"      Renal &mdash; There have been 78 reported cases of acute renal failure or renal insufficiency in patients using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/57\">",
"       57",
"      </a>",
"      ]. In a report of four patients, the time between initiation of exenatide and diagnosis of acute renal failure ranged from two to nine months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/58\">",
"       58",
"      </a>",
"      ]. All four patients presented with nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased fluid intake, and all were receiving ACE inhibitors and diuretics, which can contribute to the decline in renal function. None of the patients were taking nonsteroidal antiinflammatory drugs. After a dose reduction or withdrawal of exenatide, recovery of renal function was incomplete in three of the four patients. Renal biopsy in one patient showed ischemic glomeruli with moderate to severe interstitial fibrosis, tubular atrophy, and early diabetic nephropathy. The relationship between these findings and exenatide could not be determined.",
"      <br/>",
"      <br/>",
"      Exenatide should",
"      <strong>",
"       not",
"      </strong>",
"      be used in patients with a creatinine clearance below 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      In patients with moderate renal impairment (creatinine clearance 30 to 50",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      monitoring of serum creatinine is warranted when initiating therapy and after the usual dose increase from 5 to 10 mcg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    , available in prefilled syringes that hold a month's supply of either 5 or 10 mcg doses, is administered subcutaneously twice daily immediately before or within one hour of morning and evening meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/59\">",
"     59",
"    </a>",
"    ]. Exenatide should not be used in patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    or end stage kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/57\">",
"     57",
"    </a>",
"    ]. Caution is suggested in prescribing for patients with confirmed gastroparesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long-acting GLP-1 agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is a once daily injectable GLP-1 analog available for use in the United States, Europe, and in Japan. An extended release formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    , which is administered by subcutaneous injection once weekly, is available in the United States and Europe. Other long-acting agents (eg, albiglutide, taspoglutide) are currently in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/60-64\">",
"     60-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Liraglutide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is a GLP-1 analog that has been modified to non-covalently bind to serum albumin through a lipid side chain, resulting in slower degradation and allowing for once-daily subcutaneous dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/65\">",
"     65",
"    </a>",
"    ]. It is available for use as monotherapy as an adjunct to diet and exercise or in combination with oral agents in adults with type 2 diabetes. It is not considered a first-line therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is available in prefilled pens. The initial dose is 0.6 mg once daily for one week to reduce gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/66\">",
"     66",
"    </a>",
"    ]. After one week, the dose should be increased to 1.2 mg once daily for one week. If blood glucoses remain above the goal range, the dose can be increased to 1.8 mg once daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3950090\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    monotherapy was demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a dose response study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      monotherapy versus placebo in 165 patients with type 2 diabetes, the proportion of patients achieving an A1C of &le;7 percent was 46, 48, 38, and 5 percent for the three doses of liraglutide (1.90, 1.25, 0.65 mg) and placebo, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 52-week trial of monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      (1.2 or 1.8 mg) versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"       glimepiride",
"      </a>",
"      (8 mg) in 746 patients with recently diagnosed type 2 diabetes, the proportions of patients achieving an A1C of &le;7 percent were 43, 51, and 28 percent, respectively. Reductions in A1C were significantly greater with liraglutide 1.2 and 1.8 mg (0.84 and 1.14 percentage points versus 0.51 with glimepiride) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/67\">",
"       67",
"      </a>",
"      ]. In addition, the A1C reduction with 1.8 mg of liraglutide was greater than that with 1.2 mg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is also effective when used in combination with one (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], sulfonylureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]) or two (sulfonylurea plus metformin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/72\">",
"     72",
"    </a>",
"    ], thiazolidinediones plus metformin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/73\">",
"     73",
"    </a>",
"    ]) oral agents. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 26-week randomized trial of once daily subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      (0.6, 1.2, or 1.8 mg),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"       glimepiride",
"      </a>",
"      (4 mg daily), or placebo in 1091 patients with type 2 diabetes treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , reductions in A1C (approximately 1 percentage point) were significantly greater with liraglutide or glimepiride [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/68\">",
"       68",
"      </a>",
"      ]. Mean A1C values did not differ between the liraglutide (1.2, 1.8 mg) and glimepiride groups.",
"     </li>",
"     <li>",
"      In a 26-week randomized trial of once daily subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      (1.2 or 1.8 mg) versus oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      (100 mg) in 665 patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      alone (mean baseline A1C 8.5 percent), the mean reduction in A1C was significantly greater with either dose of liraglutide (-1.24 and -1.50 compared with -0.90 percentage points with sitagliptin) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is associated with a significant reduction in weight (treatment difference -1.4 to -3.5 kg) when compared with placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    , insulin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/61,67-69,72,73\">",
"     61,67-69,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3950097\">",
"    <span class=\"h4\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse events are nausea, vomiting, and diarrhea, occurring in the above trials at rates of 10 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/67-69,72,73\">",
"     67-69,72,73",
"    </a>",
"    ]. In five",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    trials, including over 3900 patients, there were seven cases of pancreatitis in patients randomly assigned to liraglutide and one case in a patient using another diabetes drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/74\">",
"     74",
"    </a>",
"    ]. At the current time, there are insufficient data to know if there is a causal relationship, although other GLP-1 analogs have been associated with pancreatitis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Side effects'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Adverse effects'",
"    </a>",
"    below.) Pancreatitis should be considered in patients with persistent severe abdominal pain (with or without nausea), and liraglutide should be discontinued in such patients.",
"   </p>",
"   <p>",
"    The risk of hypoglycemia is small. In one trial, minor hypoglycemia occurred in approximately 10 percent of subjects taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    monotherapy compared with 24 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rat studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    was associated with benign and malignant thyroid C-cell tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Limited data suggest that this may be a species-specific phenomenon that is mediated by the GLP-1 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/76\">",
"     76",
"    </a>",
"    ]. It is unclear whether any effect is present in humans because humans have far fewer C-cells than rats, and expression of the GLP-1 receptor in human C-cells is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/76\">",
"     76",
"    </a>",
"    ]. There were no changes in calcitonin levels in short-term human studies, but medullary thyroid carcinoma may take years to develop and its low prevalence complicates any quantification of risk. The potential effect of liraglutide and other long-acting GLP-1 receptor agonists and mimetics on thyroid C-cells in humans requires further investigation. Until such data are available, liraglutide is not recommended for use in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Exenatide once weekly",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sustained-release formulation of subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    , exenatide once weekly (median half-life of two weeks), is available in Europe and the United States. It reduces A1C levels in patients with type 2 diabetes who are inadequately controlled with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diet and exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/60,77,78\">",
"     60,77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3950104\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy was demonstrated in a randomized trial evaluating the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    once weekly (2.0 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    (once daily) to oral agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    with or without sulfonylurea) in 456 adults with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/77\">",
"     77",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean reduction in A1C at 26 weeks was slightly but significantly greater in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      once weekly group (-1.5 versus -1.3 percentage points with glargine). Goal A1C (&lt;7.0 percent) was achieved by 60 and 48 percent of patients randomly assigned to exenatide once weekly and glargine, respectively. The clinical importance of the small difference in A1C is uncertain. In addition, it is unclear if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"       insulin glargine",
"      </a>",
"      was adequately titrated, since only 21 percent of patients taking insulin glargine had fasting glucose levels within the goal range (72 to 99",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.0 to 5.5",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      Hypoglycemia was reported most frequently in patients receiving concomitant sulfonylurea, but the overall frequency was lower in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      once weekly group (8 versus 26 percent).",
"     </li>",
"     <li>",
"      Weight loss occurred more frequently in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      once weekly versus glargine (-2.6 versus +1.4 kg).",
"     </li>",
"     <li>",
"      More patients discontinued",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      once weekly than glargine due to nausea and injection site reactions, which occurred in 13 percent of patients in the exenatide group compared with 1 to 2 percent in the glargine group. Pancreatitis occurred in one patient treated with exenatide once weekly. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3950111\">",
"    <span class=\"h4\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    once weekly are similar to those of the twice daily formulation. Nausea is the most frequent adverse event, but it has been reported less frequently with once weekly than with twice daily administration (26 versus 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/60\">",
"     60",
"    </a>",
"    ]. Other side effects include vomiting and injection site pruritus. There are no data evaluating exenatide once weekly&rsquo;s effect on the incidence of major adverse cardiovascular events or pancreatic cancer.",
"   </p>",
"   <p>",
"    Stimulation of calcitonin release was reported in rats exposed to continuous but not intermittent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/76\">",
"     76",
"    </a>",
"    ]. This raises concern for the potential of tumorigenesis of exenatide once weekly, as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/76\">",
"     76",
"    </a>",
"    ]. There were no changes in calcitonin levels in short-term human studies, but long-term surveillance is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Long-term safety data are lacking. Until such data are available, exenatide once weekly is not recommended for use in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparison of GLP-1 receptor analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a growing number of trials directly comparing GLP-1 receptor analogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/62,80-82\">",
"     62,80-82",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two similarly designed non-inferiority trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      once weekly (2 mg) versus the twice daily formulation (10 micrograms) in a combined total of 547 patients with type 2 diabetes (mean A1C 8.3), the improvement in A1C (-1.9 versus -1.5 percentage points in one study and -1.6 versus -0.9 percentage points in the other) was better with exenatide once weekly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/80,82\">",
"       80,82",
"      </a>",
"      ]. Goal A1C (&lt;7 percent) was achieved by 77 and 61 percent of patients in the longer (30 weeks) study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/80\">",
"       80",
"      </a>",
"      ] and by 58 and 30 percent of patients in the shorter (24 weeks) study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/82\">",
"       82",
"      </a>",
"      ]. There were similar reductions in body weight.",
"     </li>",
"     <li>",
"      A 26-week trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      (1.8 mg daily) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      (10 micrograms twice daily) in 464 patients who were inadequately controlled (mean A1C 8.2 percent) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , sulfonylureas, or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/81\">",
"       81",
"      </a>",
"      ]. There was a significantly greater reduction in A1C with liraglutide than exenatide (1.12 versus 0.79 percentage points), which was primarily due to improved fasting glucose with liraglutide. Nausea, vomiting, and diarrhea were the most common side effects and occurred with equal frequency in both groups (approximately 27, 8, and 12 percent, respectively). Weight loss was also similar in the two groups (2.8 to 3.2 kg).",
"     </li>",
"     <li>",
"      Another 26 week trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      (1.8 mg daily) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      lar (2 mg once weekly) in 911 patients who were inadequately controlled (mean A1C approximately 8.4 percent) with oral antihyperglycemic drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , sulfonylureas,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      [monotherapy or in combination]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/83\">",
"       83",
"      </a>",
"      ]. There was no significant difference in mean change in A1C (-1.48 versus -1.28 percent with exenatide). The most common side effects, nausea (21 versus 9 percent), diarrhea (13 versus 6 percent), and vomiting (11 versus 4 percent), occurred more frequently in the liraglutide group. Weight loss was slightly greater in the liraglutide group (-3.57 and 2.68 kg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are currently no comparative trials with long-term outcomes, such as diabetic complications, health-related quality of life, or mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DPP-4 INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dipeptidyl peptidase 4 (DPP-4) is a ubiquitous enzyme expressed on the surface of most cell types that deactivates a variety of other bioactive peptides, including GIP and GLP-1; therefore, its inhibition could potentially affect glucose regulation through multiple effects (",
"    <a class=\"graphic graphic_table graphicRef51832 \" href=\"mobipreview.htm?11/44/11979\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/19\">",
"     19",
"    </a>",
"    ]. These inhibitors, unlike other GLP-1-based therapies, can be administered orally.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     linagliptin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    are the DPP-4 inhibitors available for the treatment of type 2 diabetes in the United States and many other countries. Vildagliptin is available in several countries, but not in the US.",
"   </p>",
"   <p>",
"    DPP-4 inhibitors are not considered as initial therapy for the majority of patients with type 2 diabetes. They can be considered as monotherapy in patients who are intolerant of or have contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas, or thiazolidinediones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sitagliptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    is a DPP-4 inhibitor that is approved for the treatment of type 2 diabetes (as monotherapy, a second agent in those who do not respond to a single agent, such as a sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or a thiazolidinedione, and as a third agent when dual therapy with metformin and a sulfonylurea does not provide adequate glycemic control). The usual dose of sitagliptin is 100 mg once daily, with reduction to 50 mg for moderate to severe renal insufficiency (GFR 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and 25 mg for severe renal insufficiency (&lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    monotherapy was demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an 18-week randomized trial of patients with type 2 diabetes and an average baseline A1C of 8.1 percent,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      100 mg compared with placebo resulted in an absolute A1C reduction of 0.6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 24-week trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      (100 or 200 mg) in 741 patients with type 2 diabetes, there were similar improvements in A1C values and fasting plasma glucose concentrations in both sitagliptin groups compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/86\">",
"       86",
"      </a>",
"      ]. Patients with baseline A1C values &ge;9 percent had greater reductions in A1C values compared with those with baseline A1C values &lt;8 percent (-1.52 percent versus -0.57 percent). The incidence of hypoglycemia was similar among groups, but the proportion of patients reporting gastrointestinal side effects was slightly higher in the sitagliptin group (16.4 versus 11.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    is also effective when used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/87-89\">",
"     87-89",
"    </a>",
"    ], thiazolidinediones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/90\">",
"     90",
"    </a>",
"    ], or sulfonylureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/91\">",
"     91",
"    </a>",
"    ] and, in one study, it had similar A1C-lowering efficacy as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/89\">",
"     89",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 24-week randomized trial in 701 patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      improved A1C (-0.6 percentage points from baseline), fasting glucose, and two-hour postprandial glucose concentrations compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 24-week randomized trial in 353 patients with type 2 diabetes, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      improved A1C (-0.85 percentage points from baseline) and fasting plasma glucose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/90\">",
"       90",
"      </a>",
"      ]. The between treatment difference (sitagliptin - placebo) was -0.70 percent. There were more gastrointestinal side effects with sitagliptin compared with placebo (13.7 versus 6.2 percent).",
"     </li>",
"     <li>",
"      In a 52-week randomized trial in 1172 patients inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      resulted in a similar reduction in A1C of 0.7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/89\">",
"       89",
"      </a>",
"      ]. However, the addition of glipizide was associated with more hypoglycemia and weight gain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/58/2983?source=see_link\">",
"     Sitagliptin-metformin",
"    </a>",
"    is available in a single tablet (50",
"    <span class=\"nowrap\">",
"     mg/500",
"    </span>",
"    mg and 50",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , respectively) that is taken twice daily with meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/92\">",
"     92",
"    </a>",
"    ]. Sitagliptin is also available combined with extended release metformin (50",
"    <span class=\"nowrap\">",
"     mg/500",
"    </span>",
"    mg, 50",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    mg, 100",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    mg of sitagliptin and extended release metformin, respectively) that is taken once daily with the evening meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Saxagliptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     Saxagliptin",
"    </a>",
"    is approved as initial pharmacologic therapy for the treatment of type 2 diabetes or as a second agent in those who do not respond to a single agent, such as a sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , or a thiazolidinedione. The usual dose of saxagliptin is 2.5 or 5 mg once daily, with the 2.5 mg dose recommended for patients with moderate to severe chronic kidney disease (GFR &le;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and for patients taking strong cytochrome P450",
"    <span class=\"nowrap\">",
"     3A4/5",
"    </span>",
"    inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     Saxagliptin",
"    </a>",
"    monotherapy reduces A1C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. As an example, in an 24-week randomized trial of saxagliptin (2.5, 5, or 10 mg daily) versus placebo in 401 patients with treatment-naive type 2 diabetes and an average baseline A1C of 7.9 percent, saxagliptin resulted in A1C reductions of 0.4, 0.5, and 0.5 percentage points, respectively, compared with an increase of 0.2 percentage points in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     Saxagliptin",
"    </a>",
"    is also effective when used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/97,98\">",
"     97,98",
"    </a>",
"    ], sulfonylureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/99\">",
"     99",
"    </a>",
"    ], or thiazolidinediones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/94\">",
"     94",
"    </a>",
"    ]. As an example, in a 24-week trial of 743 patients inadequately controlled with metformin monotherapy (1500 to 2500",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    the addition of saxagliptin (2.5 or 5 mg once daily) versus placebo improved A1C (-0.6 and -0.7 versus +0.1 percentage points from baseline) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40822?source=see_link\">",
"     Saxagliptin-metformin",
"    </a>",
"    is available in a single tablet (5",
"    <span class=\"nowrap\">",
"     mg/500",
"    </span>",
"    mg, 5",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    mg, 2.5",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    and extended-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , respectively) that is taken once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vildagliptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vildagliptin is another DPP-4 inhibitor available for use in some countries, although it has not been approved by the FDA. It is effective as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/101-104\">",
"     101-104",
"    </a>",
"    ] or in combination with metformin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/105,106\">",
"     105,106",
"    </a>",
"    ], thiazolidinediones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/107\">",
"     107",
"    </a>",
"    ], or insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/108\">",
"     108",
"    </a>",
"    ], as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 12-week trial, 279 patients with type 2 diabetes were randomly assigned to one of four doses of vildagliptin or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/101\">",
"       101",
"      </a>",
"      ]. The higher doses of vildagliptin (50 or 100 mg daily) were associated with significant reductions in A1C compared with placebo (between treatment differences of -0.43 and -0.40 percent, respectively).",
"     </li>",
"     <li>",
"      In two randomized trials, the addition of vildagliptin (50 or 100 mg daily) compared with placebo improved A1C in patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (between group differences of -0.6 to -1.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/105,106\">",
"       105,106",
"      </a>",
"      ]. In the patients with the highest A1C values at baseline (&gt;8.5 percent), only 7.5, 16.3, and 2.1 percent of patients receiving 50 mg vildagliptin, 100 mg vildagliptin or placebo, respectively, achieved an A1C of &lt;7.0 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 24-week trial of vildagliptin versus placebo in 296 patients with type 2 diabetes suboptimally treated with insulin, the addition of vildagliptin (50 mg twice daily) significantly, but modestly, improved A1C (between group difference -0.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In studies of previously untreated patients, vildagliptin had similar A1C-lowering efficacy as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , but was less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. As an example, in a 52-week non-inferiority study of vildagliptin (100 mg daily) versus metformin (titrated to 2000 mg daily) in 780 patients with previously untreated type 2 diabetes, metformin was superior (vildagliptin was not found to be non-inferior) in reducing A1C values (between group difference 0.4 percent, 95% CI 0.28-0.65) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/110\">",
"     110",
"    </a>",
"    ]. Goal A1C (&lt;7.0 percent) was achieved by 45 and 35 percent of those who received metformin and vildagliptin, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283607\">",
"    <span class=\"h2\">",
"     Linagliptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     Linagliptin",
"    </a>",
"    is available for use as an adjunct to diet and exercise in adults with type 2 diabetes. The efficacy of linagliptin as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/111\">",
"     111",
"    </a>",
"    ], and in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/112,113\">",
"     112,113",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/114\">",
"     114",
"    </a>",
"    ], combined metformin and sulfonylurea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/115\">",
"     115",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/116\">",
"     116",
"    </a>",
"    ] is illustrated by the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 503 patients with diabetes were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"       linagliptin",
"      </a>",
"      (5 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/111\">",
"       111",
"      </a>",
"      ]. After 24 weeks, A1C decreased by 0.44 percentage points in the linagliptin group compared with an increase of 0.25 percentage points in the placebo group.",
"     </li>",
"     <li>",
"      In a 24-week trial, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"       linagliptin",
"      </a>",
"      (5 mg daily) versus placebo improved A1C in patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (mean change from baseline -0.49 versus +0.15 percentage points) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 24-week trial, 1058 patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and a sulfonylurea were randomly assigned to the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"       linagliptin",
"      </a>",
"      (5 mg) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/115\">",
"       115",
"      </a>",
"      ]. The reduction in A1C was significantly greater in the linagliptin group (mean change from baseline -0.72 versus -0.10 percentage points).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few head-to-head trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     linagliptin",
"    </a>",
"    to other agents. In a two year non-inferiority study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    (1 to 4 mg, mean dose 3 mg) versus linagliptin (5 mg), both administered once daily, in 1551 patients with type 2 diabetes inadequately controlled on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (mean baseline A1C 7.7 percent), the adjusted mean change in A1C was better with glimepiride (-0.36 versus -0.16 percent), although linagliptin was not found to be statistically inferior to glimepiride [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/117\">",
"     117",
"    </a>",
"    ]. The A1C reduction for both drugs in this long-term study was small. This may be related to adjustment for baseline factors (baseline A1C, treatment arm, and prior antidiabetic drugs) or to the high drop-out rate (~40 percent), as missing data was imputed via the last observation carried forward method. The addition of glimepiride was associated with more hypoglycemia (36 versus 7 percent of patients) and weight gain (+1.3 versus -1.4 kg with linagliptin). There were too few cardiovascular events to draw any meaningful conclusions.",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     linagliptin",
"    </a>",
"    is 5 mg once daily, taken with or without food. It is primarily eliminated via the enterohepatic system. No dose adjustment is necessary in patients with renal or hepatic impairment. Inducers of CYP3A4 or P-glycoprotein (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) may decrease the efficacy of linagliptin. Therefore, patients requiring such drugs should receive an alternative to linagliptin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/37/27222?source=see_link\">",
"     Linagliptin-metformin",
"    </a>",
"    is available in a single tablet (2.5",
"    <span class=\"nowrap\">",
"     mg/500",
"    </span>",
"    mg, 2.5",
"    <span class=\"nowrap\">",
"     mg/850",
"    </span>",
"    mg, 2.5",
"    <span class=\"nowrap\">",
"     mg/1000",
"    </span>",
"    mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     linagliptin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , respectively) that is taken twice daily with meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9933475\">",
"    <span class=\"h2\">",
"     Alogliptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     Alogliptin",
"    </a>",
"    is available for use as an adjunct to diet and exercise in adults with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/118\">",
"     118",
"    </a>",
"    ]. Alogliptin is effective as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/119\">",
"     119",
"    </a>",
"    ] and in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/120\">",
"     120",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/121\">",
"     121",
"    </a>",
"    ], pioglitazone plus metformin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/122\">",
"     122",
"    </a>",
"    ], sulfonylureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/123\">",
"     123",
"    </a>",
"    ], or insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/124\">",
"     124",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 12-week trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"       alogliptin",
"      </a>",
"      (12.5 or 25 mg once daily) versus placebo in 288 patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (500 or 750 mg daily), there were greater reductions in A1C in the active treatment group (-0.55, -0.64, and +0.22 percent for 12.5 mg, 25 mg, and placebo, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In similarly designed 26-week trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"       alogliptin",
"      </a>",
"      (12.5 or 25 mg once daily) versus placebo in patients with type 2 diabetes inadequately controlled with a stable dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      (n = 500) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/123\">",
"       123",
"      </a>",
"      ] or insulin (monotherapy or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , n = 390) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/124\">",
"       124",
"      </a>",
"      ], there were greater reductions in A1C in the alogliptin groups (mean change in A1C from baseline -0.39, -0.53, and +0.01 percentage points for the 12.5, 25 mg, and placebo groups, respectively, in the glyburide trial and -0.63, -0.71, and -0.13 percent, respectively, in the insulin trial).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For initial therapy in patients with type 2 diabetes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    has not been shown to be superior to short-term dietary intervention. In a three-month trial comparing alogliptin to a traditional Japanese diet (unspecified low fat-low calorie) in 50 patients with newly diagnosed type 2 diabetes, there were similar reductions in A1C in both groups (-1.77 and -1.62 percentage points) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/125\">",
"     125",
"    </a>",
"    ]. Patients randomly assigned to the traditional Japanese diet lost significantly more weight (change in BMI -0.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    versus -0.1).",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    is 25 mg once daily, with dose reductions to 12.5 mg once daily in patients with creatinine clearance between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and to 6.25 mg daily in patients with creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or undergoing dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     Alogliptin",
"    </a>",
"    is also available in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Comparison of DPP-4 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DPP-4 inhibitors appear to have similar efficacy. In an 18-week trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    (5 mg) versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    (100 mg) in 800 patients inadequately controlled on a stable dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , there were similar reductions in A1C (-0.52 versus -0.62 percentage points) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/127\">",
"     127",
"    </a>",
"    ]. In addition, the results from a meta-analysis of studies comparing sitagliptin to placebo or vildagliptin to placebo suggest similar efficacy (weighted mean difference in A1C values of -0.74 and -0.73 percent, 95% CI -0.84 to -0.63 and -0.94 to -0.52, for sitagliptin and vildagliptin compared with placebo, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/36\">",
"     36",
"    </a>",
"    ]. A second meta-analysis of sitagliptin and vildagliptin trials reported similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the DPP-4 inhibitors result in modest improvement in A1C. However, there are no data on long-term safety, mortality, diabetic complications, or health-related quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DPP-4 inhibitors were well tolerated in short-term studies. There are no effects on body weight or risk of hypoglycemia (in the absence of concomitant treatment with insulin or sulfonylureas). Commonly reported side effects include headache, nasopharyngitis, and upper respiratory tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/36,94,111,129,130\">",
"     36,94,111,129,130",
"    </a>",
"    ]. The long-term safety with DPP-4 inhibitors has not been established.",
"   </p>",
"   <p>",
"    Although the DPP-4 inhibitors are relatively specific for GLP-1, the long-term consequences of DPP-4 inhibition and its effects on other DPP-4 substrates are unknown. Due to the ubiquitous nature of dipeptidyl peptidase substrates and the variable specificity of DPP-4 inhibitors, each agent within this class will need to be scrutinized individually for drug-specific side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/131\">",
"     131",
"    </a>",
"    ]. It is possible that the risk of side effects may be higher with less selective DPP-4 inhibitors. Residual crossover with other substrates of DPP-4, particularly with respect to immune function, remains a concern, although this has not been reported in short-term clinical trials. However, a meta-analysis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    and vildagliptin studies with available side effect data reported a small increased risk of nasopharyngitis (risk ratio [RR] 1.2, 95% CI 1.0-1.4), urinary tract infection (RR 1.5, 95% CI 1.0-2.2), and headache (RR 1.4, 95% CI 1.1-1.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/36\">",
"     36",
"    </a>",
"    ]. A subsequent meta-analysis of trials (18 to 104 weeks duration) comparing a DPP-4 inhibitor (sitagliptin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    , vildagliptin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     linagliptin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    ) with placebo (44 trials), a comparator from another class of antidiabetic agents (20 trials) or another DPP-4 inhibitor (three trials) showed a small increased risk of nasopharyngitis compared with placebo (6 versus 5.3 percent, RR 1.13, 95% CI 0.99-1.29), which was predominantly driven by the sitagliptin subgroup (5.3 versus 4.1 percent, RR 1.35, 95% CI 1.03-1.77) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/129\">",
"     129",
"    </a>",
"    ]. The risk of upper respiratory and urinary tract infections was not significantly elevated, whereas the risk of dizziness and headache was slightly elevated (8.2 versus 7.5 percent, RR 1.14, 95% CI 1.02-1.26). In the three head-to-head trials, there were no clinically significant differences in adverse effects among DPP-4 inhibitors. There were too few events to report meaningful data on cardiovascular or mortality outcomes.",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/86,90\">",
"     86,90",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/85,87,106\">",
"     85,87,106",
"    </a>",
"    ], studies have reported a slight increased risk of gastrointestinal side effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    . In addition, there have been postmarketing case reports of acute pancreatitis in patients using sitagliptin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/50,132,133\">",
"     50,132,133",
"    </a>",
"    ]. This finding is similar to case reports describing pancreatitis in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    . In a retrospective cohort study of a claims database, the incidence of acute pancreatitis in sitagliptin users was 5.6 cases per 1000 patient-years, which was similar to the incidence in the diabetic control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/52\">",
"     52",
"    </a>",
"    ]. However, in a population-based case-control study using a large insurance database, treatment with GLP-1-based therapy (sitagliptin and exenatide) was associated with an increased risk of hospitalization for acute pancreatitis (adjusted OR 2.07, 95% CI 1.36-3.13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/51\">",
"     51",
"    </a>",
"    ]. It is unclear if exposure to DPP-4 inhibitors or other drugs that act through GLP-1 play a causal role in the development of pancreatitis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Side effects'",
"    </a>",
"    above.) Pancreatitis should be considered in patients with persistent severe abdominal pain (with or without nausea), and DPP-4 inhibitors should be discontinued in such patients. DPP-4 inhibitors should be used with caution and with careful monitoring in patients with a history of pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/130,132\">",
"     130,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although uncommon, cases of hepatic dysfunction (liver enzyme elevations, hepatitis) have been reported in patients taking vildagliptin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/130,134\">",
"     130,134",
"    </a>",
"    ]. As a result, liver function tests should be evaluated prior to initiation of vildagliptin and alogliptin, and at three-month intervals during the first year of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/134\">",
"     134",
"    </a>",
"    ]. If an increase in AST or ALT of three times the upper limit of normal or greater persists, the drugs should be discontinued.",
"   </p>",
"   <p>",
"    Some DPP-4 inhibitors, including vildagliptin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    , have been associated with serious skin reactions during preclinical studies in animals (red discoloration and swelling, blistering and flaking of skin with necrosis at higher doses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/135,136\">",
"     135,136",
"    </a>",
"    ]. Skin lesions also occurred in normal volunteers given four to six times the proposed therapeutic dose of vildagliptin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/137\">",
"     137",
"    </a>",
"    ]. In post-marketing reports,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    , saxagliptin, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30545?source=see_link\">",
"     alogliptin",
"    </a>",
"    have been associated with hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions, including Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/118\">",
"     118",
"    </a>",
"    ]. DPP-4 inhibitors are contraindicated in patients with a history of a serious hypersensitivity reaction after previous exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/25/38298/abstract/138\">",
"     138",
"    </a>",
"    ]. There are no studies of the effects of DPP-4 inhibitors on C-cell physiology or growth in animals or humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucagon-like peptide-1 (GLP-1)-based therapies reproduce or enhance the actions of the naturally occurring peptide, GLP-1, and control glucose without causing weight gain. The exact role for these drugs among the myriad of other agents for diabetes management is unclear. GLP-1-based therapies should not be used in patients with type 1 diabetes. Many questions remain unanswered regarding clinical use in type 2 diabetes, including long-term benefits and risks and their role in combination with other diabetes medications. Thus, they are not considered as initial therapy for the majority of patients with type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest an individualized approach to initiating these therapies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       Exenatide",
"      </a>",
"      (two daily injections or one weekly injection) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      (one daily injection) can be considered as an add-on drug for patients with type 2 diabetes who are poorly controlled on maximal doses of one or two oral agents and for whom hypoglycemia is of particular concern. With long-term use, weight loss can be substantial in a small fraction of treated patients and associated with other metabolic benefits. By comparison, insulin therapy generally requires only one injection, is less expensive, but is accompanied by hypoglycemia, albeit usually not severe, and weight gain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'GLP-1 analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are inadequate data to support the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/47/21238?source=see_link\">",
"       liraglutide",
"      </a>",
"      in combination with DPP-4 inhibitors or prandial insulin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Exenatide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Long-acting GLP-1 agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DPP-4 inhibitors can be considered as monotherapy in patients with type 2 diabetes who are intolerant of or have contraindications to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , sulfonylureas, or thiazolidinediones. As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"       linagliptin",
"      </a>",
"      might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia or in a patient with difficulty tolerating hypoglycemia (elderly person). They are, however, more expensive and less potent in lowering glycemia than the glinides, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      , which can also be used safely in patients with chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'DPP-4 inhibitors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link&amp;anchor=H7#H7\">",
"       \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\", section on 'Meglitinides'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DPP-4 inhibitors can be considered as add-on drug therapy for patients who are inadequately controlled on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , a thiazolidinedione, or a sulfonylurea. However, the modest glucose lowering effectiveness, expense, and limited clinical experience may temper enthusiasm for these drugs. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'DPP-4 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/1\">",
"      Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/2\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/3\">",
"      Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/4\">",
"      Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/5\">",
"      Buse, JB, Weyer, C, Maggs, DG. Amylin replacement with Pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/6\">",
"      Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87:1282.",
"     </a>",
"    </li>",
"    <li>",
"     Amylin Pharmaceuticals, Inc. Symlin prescribing information. Available at: www.symlin.com (Accessed on November 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/8\">",
"      Dungan, KM, Buse, JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clinical Diabetes 2005; 23:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/9\">",
"      Vilsb&oslash;ll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/10\">",
"      Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 2005; 128:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/11\">",
"      Dupr&eacute; J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004; 89:3469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/12\">",
"      Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90:5991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/13\">",
"      Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273:E981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/14\">",
"      Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/15\">",
"      Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2011; 2:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/16\">",
"      Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/17\">",
"      Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/18\">",
"      Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002; 143:3152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/19\">",
"      Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/20\">",
"      Parkes, D, Jodka, C, Smith, P, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/21\">",
"      Nathan DM. Finding new treatments for diabetes--how many, how fast... how good? N Engl J Med 2007; 356:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/22\">",
"      Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006; 29:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/23\">",
"      Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; :CD006423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/24\">",
"      Vilsb&oslash;ll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/25\">",
"      Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267:7402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/26\">",
"      Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50:583.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration (FDA) - Byetta file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf (Accessed on December 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/28\">",
"      Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/29\">",
"      Tang-Christensen M, Larsen PJ, G&ouml;ke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271:R848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/30\">",
"      Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/31\">",
"      Stoffers DA, Desai BM, DeLeon DD, Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 2003; 52:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/32\">",
"      DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/33\">",
"      Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/34\">",
"      Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/35\">",
"      Zinman B, Hoogwerf BJ, Dur&aacute;n Garc&iacute;a S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/36\">",
"      Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/37\">",
"      Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/38\">",
"      Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/39\">",
"      Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/40\">",
"      Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/41\">",
"      Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012; 379:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/42\">",
"      Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/43\">",
"      Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/44\">",
"      Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/45\">",
"      Davis SN, Johns D, Maggs D, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007; 30:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/46\">",
"      Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/47\">",
"      Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20:411.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. MedWatch The FDA Safety Information and Adverse Event Reporting Program: Safety Information - Byetta (exenatide) October 2007 file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150839.htm (Accessed on October 18, 2007).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Postmarket drug safety information for patients and providers. Information for healthcare professionals: Exenatide (marketed as Byetta) - 8/2008 update file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm (Accessed on September 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/50\">",
"      Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/51\">",
"      Singh S, Chang HY, Richards TM, et al. Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study. JAMA Intern Med 2013; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/52\">",
"      Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/53\">",
"      Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13:559.",
"     </a>",
"    </li>",
"    <li>",
"     F-D-C reports &mdash; The Pink Sheet 2008; 70:9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/55\">",
"      Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010; 12:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/56\">",
"      Gonzalez-Perez A, Schlienger RG, Rodr&iacute;guez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010; 33:2580.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. MedWatch The FDA Safety Information and Adverse Event Reporting Program: Safety Information - Byetta (exenatide) - Renal Failure www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm (Accessed on December 02, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/58\">",
"      Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care 2009; 32:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/59\">",
"      Linnebjerg H, Kothare PA, Skrivanek Z, et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med 2006; 23:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/60\">",
"      Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/61\">",
"      Vilsb&oslash;ll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/62\">",
"      Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/63\">",
"      Ratner R, Nauck M, Kapitza C, et al. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med 2010; 27:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/64\">",
"      Nauck MA, Ratner RE, Kapitza C, et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009; 32:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/65\">",
"      Elbr&oslash;nd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/66\">",
"      Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/67\">",
"      Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/68\">",
"      Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/69\">",
"      Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/70\">",
"      Marre M, Shaw J, Br&auml;ndle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/71\">",
"      Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/72\">",
"      Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/73\">",
"      Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32:1224.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers - Victoza (liraglutide) file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm198543.htm (Accessed on February 03, 2010).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA briefing materials - Liraglutide (April 2009) www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf (Accessed on December 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/76\">",
"      Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/77\">",
"      Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/78\">",
"      Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376:431.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/80\">",
"      Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/81\">",
"      Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/82\">",
"      Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/83\">",
"      Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/84\">",
"      Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/85\">",
"      Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/86\">",
"      Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/87\">",
"      Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/88\">",
"      Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/89\">",
"      Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/90\">",
"      Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/91\">",
"      Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/92\">",
"      Sitagliptin/metformin (Janumet) for type 2 diabetes. Med Lett Drugs Ther 2007; 49:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/93\">",
"      Linagliptin/metformin (Jentadueto) for type 2 diabetes mellitus. Med Lett Drugs Ther 2012; 54:37.",
"     </a>",
"    </li>",
"    <li>",
"     Bristol-Myers Squibb. Higlights of prescribing information: ONGLYZA (saxagliptin) tablets file://packageinserts.bms.com/pi/pi_onglyza.pdf (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/95\">",
"      Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/96\">",
"      Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-na&iuml;ve patients with type 2 diabetes. Curr Med Res Opin 2009; 25:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/97\">",
"      DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/98\">",
"      Jadzinsky M, Pf&uuml;tzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/99\">",
"      Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/100\">",
"      Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes. Med Lett Drugs Ther 2011; 53:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/101\">",
"      Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/102\">",
"      Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/103\">",
"      Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-na&iuml;ve patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/104\">",
"      Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-na&iuml;ve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/105\">",
"      Ahr&eacute;n B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/106\">",
"      Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/107\">",
"      Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/108\">",
"      Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/109\">",
"      Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/110\">",
"      Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-na&iuml;ve patients with Type 2 diabetes. Diabet Med 2007; 24:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/111\">",
"      Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of &beta;-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/112\">",
"      Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010; 27:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/113\">",
"      Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/114\">",
"      Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011; 71:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/115\">",
"      Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/116\">",
"      Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/117\">",
"      Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380:475.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/119\">",
"      DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/120\">",
"      Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012; 14:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/121\">",
"      Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-na&iuml;ve patients with type 2 diabetes. Diabetes Care 2010; 33:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/122\">",
"      DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/123\">",
"      Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/124\">",
"      Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/125\">",
"      Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug na&iuml;ve type 2 diabetes: a randomized, control trial. Endocrine 2012; 41:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/126\">",
"      Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother 2013; 14:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/127\">",
"      Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/128\">",
"      Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; :CD006739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/129\">",
"      Goo&szlig;en K, Gr&auml;ber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=87103 (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/131\">",
"      Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Information for Healthcare Professionals - Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm (Accessed on October 05, 2009).",
"    </li>",
"    <li>",
"     file://packageinserts.bms.com/pi/pi_onglyza.pdf (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     The Electronic Medicines Compendium: Galvus 50 mg tablets file://emc.medicines.org.uk/medicine/20734/SPC/Galvus+50+mg+Tablets/#CLINICAL_PRECAUTIONS (Accessed on October 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/25/38298/abstract/135\">",
"      F-D-C Reports - Pharmaceutical Approvals Monthly. 2007; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     F-D-C reports &mdash; The Pink Sheet 2007; 69:14.",
"    </li>",
"    <li>",
"     F-D-C reports &mdash; The Pink Sheet 2007; 69:10.",
"    </li>",
"    <li>",
"     Merck - Highlights of prescribing information: Januvia www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf (Accessed on December 06, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1772 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38298=[""].join("\n");
var outline_f37_25_38298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLUCAGON-LIKE PEPTIDE-1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLP-1 ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Exenatide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29018503\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29018510\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long-acting GLP-1 agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Liraglutide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3950090\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3950097\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Exenatide once weekly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3950104\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3950111\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparison of GLP-1 receptor analogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DPP-4 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sitagliptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Saxagliptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vildagliptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5283607\">",
"      Linagliptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9933475\">",
"      Alogliptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Comparison of DPP-4 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1772|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/1/43025\" title=\"figure 1\">",
"      Multihormonal regulation of glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/14/37101\" title=\"figure 2A\">",
"      Plasma concentrations A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/56/42894\" title=\"figure 2B\">",
"      Plasma concentrations B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/42/17070\" title=\"figure 2C\">",
"      Plasma concentrations C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/7/7280\" title=\"figure 3\">",
"      Metformin exenatide place",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/44/11979\" title=\"table 1\">",
"      Role of GLP-1 in glucose homeostasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_25_38299="Distribution of coronary artery for D-TGA";
var content_f37_25_38299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency distribution of the coronary patterns in transposition of the great arteries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Coronary pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usual",
"       </td>",
"       <td>",
"        66.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Circumflex from RCA",
"       </td>",
"       <td>",
"        16.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single RCA",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single LCA",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inverted",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inverted circumflex/RCA",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intramural LCA",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intramural LAD",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intramural RCA",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RCA: right coronary artery; LCA: left coronary artery; LAD: left anterior descending.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wernovsky G. Transposition of the great arteries. In: Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38299=[""].join("\n");
var outline_f37_25_38299=null;
var title_f37_25_38300="ARA criteria for SLE PI";
var content_f37_25_38300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ARA criteria for diagnosis of systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Criterion",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malar rash",
"      </td>",
"      <td>",
"       Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Discoid rash",
"      </td>",
"      <td>",
"       Erythematosus raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Photosensitivity",
"      </td>",
"      <td>",
"       Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oral ulcers",
"      </td>",
"      <td>",
"       Oral or nasopharyngeal ulceration, usually painless, observed by a physician",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arthritis",
"      </td>",
"      <td>",
"       Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Serositis",
"      </td>",
"      <td>",
"       Pleuritis - convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pericarditis - documented by EKG, rub or evidence of pericardial effusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Renal disorder",
"      </td>",
"      <td>",
"       Persistent proteinuria greater than 0.5 grams per day or greater than 3+ if quantitation not performed",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cellular casts - may be red cell, hemoglobin, granular, tubular, or mixed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurologic disorder",
"      </td>",
"      <td>",
"       Seizures",
"       <strong>",
"        OR",
"       </strong>",
"       psychosis - in the absence of offending drugs or known metabolic derangements (uremia, ketoacidosis, or electrolyte imbalance)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Hematologic disorder",
"      </td>",
"      <td>",
"       Hemolytic anemia - with reticulocytosis",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leukopenia - less than 4000/mm3 total on two or more occasions",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphopenia - less than 1500/mm3 on two or more occasions",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombocytopenia - less than 100,000/mm3 in the absence of offending drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Immunologic disorders",
"      </td>",
"      <td>",
"       Positive antiphospholipid antibody",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anti-DNA - antibody to native DNA in abnormal titer",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anti-Sm - presence of antibody to Sm nuclear antigen",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       False positive serologic test for syphilis known to be positive for at least six months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antinuclear antibody",
"      </td>",
"      <td>",
"       An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with \"drug-induced lupus\" syndrome",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38300=[""].join("\n");
var outline_f37_25_38300=null;
var title_f37_25_38301="USPSTF grade I recommendations";
var content_f37_25_38301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult screening and prevention statements of USPSTF (September 2012) I statements (balance of benefits and harms uncertain)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Service",
"       </td>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirin for CVD prevention",
"       </td>",
"       <td>",
"        Men and women &gt;age 80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for coronary heart disease by ECG, ETT, or EBCT",
"       </td>",
"       <td>",
"        Adults at increased risk of CHD events",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for coronary heart disease risk by non-traditional risk factors*",
"       </td>",
"       <td>",
"        Adults men and women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer screening by CBE",
"       </td>",
"       <td>",
"        Women ages 50 to 75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer screening with digital mammography or MRI",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for colorectal cancer with computed tomographic colonography and fecal DNA testing",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for lung cancer",
"       </td>",
"       <td>",
"        Smokers with low-dose CT or CXR or sputum cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for oral cancer",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Counseling to prevent skin cancer",
"       </td>",
"       <td>",
"        Age &gt;24 years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for skin cancer with total body exam",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for type 2 diabetes",
"       </td>",
"       <td>",
"        Adults with BP &lt;135/80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Injury prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interventions to prevent low back pain",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Routine behavioral counseling about proper use of motor vehicle occupant restraints and avoidance of alcohol while driving",
"       </td>",
"       <td>",
"        Men and women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lifestyle-related problems",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for tobacco use and provide tobacco cessation interventions",
"       </td>",
"       <td>",
"        Adolescents and children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Sexually transmitted infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Routine behavioral counseling to prevent sexually transmitted infections",
"       </td>",
"       <td>",
"        Adolescents and adults not at increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for bacterial vaginosis",
"       </td>",
"       <td>",
"        Increased-risk women",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for chlamydia",
"       </td>",
"       <td>",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Substance abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for alcohol misuse",
"       </td>",
"       <td>",
"        Adolescents",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for illicit drug use",
"       </td>",
"       <td>",
"        Adolescents and adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Vision and hearing problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for glaucoma",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for hearing loss",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Screening for impaired visual acuity",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brief interventions or peer counseling to promote breast feeding",
"       </td>",
"       <td>",
"        Women after child birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for chronic kidney disease",
"       </td>",
"       <td>",
"        Older adults (&ge;50 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for dementia",
"       </td>",
"       <td>",
"        Older adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for family and intimate partner violence",
"       </td>",
"       <td>",
"        Parents or guardians, women, older adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for hepatitis C infection",
"       </td>",
"       <td>",
"        Increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for osteoporosis in men",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for suicide risk",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screening for thyroid disease",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supplemental vitamins, A, C, and E or folic acid or antioxidant combinations",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    I: uncertain benefit.",
"    <div class=\"footnotes\">",
"     ECT: electrocardiogram; ETT: exercise tolerance test; EBCT: electron beam CT for coronary calcification; USPSTF: United States Preventive Services Task Force; CT: computed tomography; CXR: chest x-ray; CBE: clinical breast examination.",
"     <br>",
"      * hs-CRP, ankle-brachial index, carotid artery intima-media thickness, EBCT, homocysteine, lipoprotein (a).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38301=[""].join("\n");
var outline_f37_25_38301=null;
var title_f37_25_38302="Persistence of beta agonist effect over time";
var content_f37_25_38302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Persistence of beta agonist efficacy over time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 489px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean FEV1 as a percentage of the predicted value on the first and last days of treatment in patients with asthma. Therapy consisted of salmeterol (40 &micro;g twice daily), albuterol (180 &micro;g four times a day), or placebo. Both beta agonists increased the FEV1, but the effect of a single dose lasted longer with salmeterol. The beneficial effect of both agents persisted at&nbsp;twelve weeks.",
"    <div class=\"footnotes\">",
"     FEV1: forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Pearlman DS, Chervinsky P, LaForce C, et al, N Engl J Med 1992; 327:1420.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38302=[""].join("\n");
var outline_f37_25_38302=null;
var title_f37_25_38303="Stool diary blank";
var content_f37_25_38303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Stool diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 611px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_25_38303=[""].join("\n");
var outline_f37_25_38303=null;
